Synthetic lethal interactions between ATR and DNA polymerases as a novel concept for individualized cancer therapy by Job, Albert & Gallmeier, Eike (Prof. Dr.)
Aus der Klinik für InnereMedizin,
Schwerpunkt Gastroenterologie, Endokrinologie, Stoffwechsel
und klinische Infektiologie
Geschäftsführender Direktor: Prof. Dr. ThomasM. Gress
des FachbereichsMedizin der Philipps-Universität Marburg
Synthetic lethal interactions between ATR
and DNA polymerases as a novel concept
for individualized cancer therapy
Inaugural-Dissertation
zur Erlangung des Doktorgrades der Naturwissenschaften
(Dr. rer. nat.)
dem FachbereichMedizin der Philipps-Universität Marburg
vorgelegt von
Albert Job
aus Kurgan-Tjube, Tadschikistan
Marburg, 2019
Angenommen vom Fachbereich Medizin der Philipps-Universität Marburg am:
12.08.2019
Gedruckt mit Genehmigung des FachbereichsMedizin.
Dekan: Prof. Dr. Helmut Schäfer
Referent: Prof. Dr. Eike Gallmeier
1. Korreferent: Prof. Dr. Thorsten Stiewe
2. Korreferent: Prof. Dr. Guntram Suske
IContents
Page
Indices IV
Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IV
Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VI
Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VII
1 Introduction 1
1.1 Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Synthetic lethality . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.3 Polymerases and the replication of DNA . . . . . . . . . . . . . . . . 4
1.4 ATR and the DNA damage response . . . . . . . . . . . . . . . . . . 6
1.5 Previous data and aims of this project . . . . . . . . . . . . . . . . . 8
2 Methods 11
2.1 Cell culture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.2 Transfection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.3 Establishment of anATR re-expressing cell clone . . . . . . . . . . 12
2.4 Western blot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.5 Cell proliferation assay . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.6 Flow cytometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.7 Immunocytochemistry . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.8 Gene knockoutwith CRISPR/Cas9 . . . . . . . . . . . . . . . . . . . 15
2.9 Polymerase chain reaction . . . . . . . . . . . . . . . . . . . . . . . . 16
2.10 DNA fiber assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.11 Mouse xenograft tumormodel for in vivo experiments . . . . . . . . 18
2.12 Statistical analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
3 Material 20
3.1 Cell lines and other organisms . . . . . . . . . . . . . . . . . . . . . 20
3.2 Equipment, software, and expendable materials . . . . . . . . . . . 20
3.3 Chemicals, reagents, solutions, andmedia . . . . . . . . . . . . . . 23
3.4 Antibodies and primer . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Contents II
Page
4 Results 31
4.1 Characterizing the synthetic lethal relationship between ATR and
PRIM1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
4.1.1 Verifying the synthetic lethality of ATR and PRIM1 . . . . . 31
4.1.2 Sensitizing various cancer cell lines to ATR and CHK1 inhib-
itors through PRIM1 depletion . . . . . . . . . . . . . . . . . 33
4.1.3 Assessing themolecularmechanism of the synthetic lethal
relationship betweenATR and PRIM1 . . . . . . . . . . . . . 34
4.2 Assessing the impact of POLD1 variants of uncertain significance to
treatmentwith ATR pathway inhibitors . . . . . . . . . . . . . . . . 39
4.2.1 Establishing heterozygous POLD1-knockout clones by using
CRISPR/Cas9 . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
4.2.2 Characterizing the functional impact of various POLD1 vari-
ants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
4.2.3 Assessing the impact of POLD1R689W on the sensitivity of
DLD-1 cells to ATR pathway inhibitors in vitro . . . . . . . . 42
4.2.4 Assessing the impact of POLD1R689W on the sensitivity of
DLD-1 cells to the ATR inhibitor AZD6738 in vivo . . . . . . 43
5 Discussion 46
5.1 Inactivation of PRIM1 function sensitizes cancer cells to ATR and
CHK1 inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
5.1.1 Verifying the synthetic lethality . . . . . . . . . . . . . . . . 46
5.1.2 In vitro validation . . . . . . . . . . . . . . . . . . . . . . . . . 47
5.1.3 Mechanistic insights . . . . . . . . . . . . . . . . . . . . . . . 47
5.1.4 Role of PRIM1 in cancer . . . . . . . . . . . . . . . . . . . . . 48
5.1.5 Future studies . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
5.2 Sensitizationof DLD-1cancer cells toATRpathwayinhibitors through
the POLD1R689W variant . . . . . . . . . . . . . . . . . . . . . . . . . 50
5.2.1 POLD1-knockout . . . . . . . . . . . . . . . . . . . . . . . . . 50
5.2.2 Mechanistic insights . . . . . . . . . . . . . . . . . . . . . . . 50
5.2.3 In vitro and in vivo validation . . . . . . . . . . . . . . . . . . 51
5.2.4 Comparisonwith theoretical prediction tools . . . . . . . . 52
5.2.5 Clinical implications . . . . . . . . . . . . . . . . . . . . . . . 54
5.2.6 Future studies . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
5.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
6 Abstract 56
Contents III
Page
7 Zusammenfassung 58
8 Bibliography 60
A Appendix VIII
A.1 Publications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . XII
A.2 Curriculumvitae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . XIII
A.3 Academic teachers . . . . . . . . . . . . . . . . . . . . . . . . . . . . XIV
A.4 Acknowledgment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . XVI
A.5 Ehrenwörtliche Erklärung . . . . . . . . . . . . . . . . . . . . . . . . XVII
IV
Indices
Abbreviations
5-FU 5-fluorouracil
ATR ataxia telangiectasia and Rad3-related protein
BRCA1/2 breast cancer 1 or 2
BSA bovine serum albumin
cDNA complementaryDNA
CldU 5-chloro-2′-deoxyuridine
COSMIC Catalogue Of SomaticMutations In Cancer
CRC colorectal cancer
ctrl control
DAPI 4’,6-diamidino-2-phenylindole
ddNTP dideoxyribonucleotide triphosphate
DDR DNA damage response
DMSO dimethyl sulfoxide
dNTP deoxyribonucleotide triphosphate
DSB double-strand break
DTT dithiothreitol
FBS fetal bovine serum
gRNA guide RNA
HR homologous recombination
HRP horseradish peroxidase
HU hydroxyurea
ICL interstrand-crosslinking
IdU 5-iodo-2′-deoxyuridine
IR ionizing radiation
KO knockout
LHA left homology arm
MCM minichromosomemaintenance
MMC mitomycin C
NTC nontransfected cells
PAM protospacer adjacent motif
PARP poly (ADP-ribose) polymerase
Indices V
PBS phosphate buffered saline
PMSF phenylmethylsulfonyl fluoride
Pol polymerase
pre-RC pre-replication complex
PuroR puromycin resistance
PVDF polyvinylidene fluoride
RHA right homology arm
RT room temperature
SDS sodium dodecyl sulfate
siPRIM1 siRNA targeting PRIM1
siRNA small interfering RNA
ssDNA single-strand DNA
TLS translesion DNA synthesis
VUS variant of uncertain significance
WT wild type
Indices VI
Figures
Page
1 Cancer caused death rate in Germany . . . . . . . . . . . . . . . . . 2
2 The concept of synthetic lethality . . . . . . . . . . . . . . . . . . . 4
3 Schematic illustration of a replication bubble . . . . . . . . . . . . . 5
4 Recruitment and activation of ATR . . . . . . . . . . . . . . . . . . . 7
5 Disruption of POLD1 exon 2a by integrating a repair template . . . 16
6 Schematic depiction of the application schedule . . . . . . . . . . . 18
7 Verification of the synthetic lethality between ATR and PRIM1 in
DLD-1 cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
8 Sensitizationof DLD-1 cells toATRandCHK1 inhibitorsuponPRIM1
depletion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
9 Sensitization of RKO, SW480, and PaTu 8988t cells to ATR andCHK1
inhibitors upon PRIM1 depletion . . . . . . . . . . . . . . . . . . . . 35
10 Impairment of cell cycle progression inATRs/s cells upon PRIM1 de-
pletion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
11 Induction of apoptosis inATRs/s cells upon PRIM1 depletion . . . . 37
12 Generation of a DLD-1 POLD1-knockout via CRISPR/Cas9 . . . . . 40
13 Allele-specific localization of POLD1 variants in DLD-1 cells . . . 41
14 Functional characterization of POLD1R689W in DLD-1 cells . . . . . 42
15 Sensitization of DLD-1 cells to ATR and CHK1 inhibitors in vitrome-
diated by POLD1R689W . . . . . . . . . . . . . . . . . . . . . . . . . . 43
16 Sensitization of DLD-1 cells to the ATR inhibitor AZD6738 in vivo
mediated by POLD1R689W . . . . . . . . . . . . . . . . . . . . . . . . 44
17 Map of the Cas9 plasmid . . . . . . . . . . . . . . . . . . . . . . . . . VIII
18 Map of the repair template plasmid . . . . . . . . . . . . . . . . . . IX
19 PCR programs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IX
20 Representative depiction of DNA fibers . . . . . . . . . . . . . . . . XI
Indices VII
Tables
Page
1 Equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2 Software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
3 ExpendableMaterial . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
4 Chemicals and Reagents . . . . . . . . . . . . . . . . . . . . . . . . . 23
5 Media, buffer, and solutions . . . . . . . . . . . . . . . . . . . . . . . 25
6 Primary antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
7 Secondary antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
8 Primer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
9 Pathogenicity for POLD1 variants according to different prediction
tools . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
10 PCR conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . X
11
Introduction
1.1 Cancer
Malignant tumors, colloquially often termed cancer, arise from autologous cells
through the accumulation of various genetic alterations, which frequently occur
in proto-oncogenes and/or tumor suppressor genes. This process is called malig-
nant transformation. Proto-oncogenes,which encode for growth factor receptors
or transcription factors, regulate cell proliferation. Genetic alterations affecting
protein function, gene expression, or copynumber result in uncontrolled cell pro-
liferation. Proto-oncogenes altered by such a gain-of-function variant are called
oncogenes. The fusion gene BCR-ABL1, a hyper-active tyrosine kinase caused by
chromosomal translocation, induces chronic myeloid leukemia, and is one example
for oncogenes giving rise to cancer [24]. Tumor suppressor genes and their subgroup
of genomemaintenance genes regulate the cellular processes of cell cycle progres-
sion or apoptosis as well as DNA repair, respectively. Genetic alterations within
these genes result in a loss-of-function and thus in accumulation of DNA damage
and/or a disturbed balance between cell proliferation and apoptosis. One prominent
example for a genetically altered tumor suppressor gene in various cancers is TP53,
which encodes thewell studied transcription factor p53 protein [64]. Additionally to
proto-oncogenes and tumor suppressor genes, genetic alterations are also necessary
in genes responsible for cell metabolism or angiogenesis to overcome the tumor’s
increased need for nutrients, energy, and oxygen [65, 96]. Such genetic alterations
often occur spontaneously, but may also be caused by exogenous factors, includ-
ing ionizing radiation, pathogens (e. g. human papillomavirus), or chemicals, like
benzene.
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Figure 1 | Cancer caused death rate in Germany
Depiction of the age-standardized (European standard) death rate caused by cancer per
100000 population for female (left) and male (right) in Germany, which is continuously
decreasing in the last two decades from 1995 to 2015 [35].
In 2015 cancerwas the cause of about 25% of all deaths (925 200) in Germany,
and although it represents the secondmost common cause of death after diseases
of the cardiovascular system [90] the death rate in the last two decades in Germany
is continuously decreasing (Figure 1) [35]. On the one hand, this may be explained
by diagnostic procedures, gettingmore sensitive, and a broader range of preven-
tive checkups, enabling an early cancer diagnosis and treatment, thus increasing
survival rates. On the other hand, research led to various additional andmore spe-
cific therapeutic approaches. So far, there are three approaches for cancer therapy,
which are the surgical resection of the tumor, the radio- aswell as the chemother-
apy. The disadvantages of these approaches are the inoperability of some tumors
due to their localization and the toxicity of the radio- and chemotherapynot only
for cancer cells but also for healthy cells. The latter two causing severe negative
side effects, including diarrhea, vomiting, hair loss, or bonemarrow suppression.
Consequentially, this resulted in the necessity of therapies being individualized
and targeted, and finally led to a fourth approach in cancer therapy: the targeted
therapy. A successful and already clinically applicable approach of targeted therapy
is based on smallmolecules ormonoclonal antibodies, impairing the target’s protein
function to aim at tumorswith oncogenic gain-of-function variants [52]. One such
example is the treatment of chronicmyeloid leukemia patientswith imatinib (brand
name Glivec), targeting the alreadymentioned hyper-active fusion tyrosine kinase
BCR-ABL1 [15]. The treatment of tumorswith defects in tumor suppressor/genome
maintenance geneswith inhibiting small molecules is not possible, as the protein
function is already impaired due to their loss-of-function variants. However, the
defective tumor suppressor/genomemaintenance genes cause an increased sensitiv-
ity to agents inducing additional DNA damage, like interstrand-crosslinking (ICL)
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agents, thus representing one approach to treat tumorswith loss-of-function vari-
ants. Furthermore, tumorswith defective tumor suppressor/genomemaintenance
genes are hyper-dependent on other compensatoryDNA repair pathways. These
relationships could be attributable to synthetic lethal interactions, and thus offer
another therapeutic approach to treat tumorswith loss-of-function variants. The
concept of synthetic lethality and its clinical significance are described below.
1.2 Synthetic lethality
Synthetic lethality describes a relationship between two genes, inwhich the impair-
ment of one of these two genes is not lethal, but the combined impairment of both
genes results in cell death. The concept was first described by Calvin Bridges in
1922,who observed lethality in aDrosophila melanogaster population due to the com-
bination of certain alterations [10]. Later the term “synthetic lethality”was coined
byTheodore Dobzhansky in 1946 [22]. Although, this concept was originally de-
scribedas analteration-mediatedgene impairment, it is todayalso applied toprotein
impairment mediated by chemical compounds. From a clinical perspective, syn-
thetic lethalityoffers anovel concept of therapyfor cancer patients. As cancers often
accumulate characteristic gene defects during the process of tumorigenesis (Fig-
ure 2a + b), they become hyper-dependent on genes,which have a synthetic lethal
relationship to the defective cancer driven gene, and thus compensate its functional
loss. Applying a chemical inhibitor targeting this compensatory genewould induce
synthetic lethality, and ultimately result in cell death (Figure 2c). Thus, patients
would benefit from a tumor-genotype specific cancer therapywith less negative side
effects, as the inhibitor treatmentwould only target cancer but not healthy cells [46].
The potential applicability of synthetic lethality for an individualized and tar-
geted cancer treatmentwas already suggested in 1997 byHartwell et al. [39], before
2005 two groups showed the possibility to treat cancers with deficiencies in the
breast cancer 1 or 2 (BRCA1/2) genes, both involved in the repair of DNA double-
strand breaks (DSBs) via homologous recombination (HR),with inhibitors targeting
poly (ADP-ribose) polymerase (PARP), a protein involved in DNA repair, by exploit-
ing their synthetic lethal relationship [11, 27]. These data led to the investigation
of various PARP inhibitors in clinical trials (comprehensively reviewed by Lord
& Ashworth [55]), and ultimately in 2014 to the first clinical approval of drugs
exploiting synthetic lethality by the U. S. Food and Drug Administration and the
European Medicines Agency. Beside BRCA1/2 and PARP, as the probably most
prominent example for clinical applicability of synthetic lethality, various other
therapeutic approaches based on synthetic lethal relationships are currently in-
vestigated. One such example is the application of chemical inhibitors targeting
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Figure 2 | The concept of synthetic lethality
a | A healthy cell with intact genes A and B. b | During the process of tumorigenesis, one of
the two genes A or B becomes impaired due to genetic alterations. As the respective second
gene compensates for the loss of thefirst genes, these cancers cells becomehyper-dependent
on the compensatory gene, but remain viable. c | Targeting the intact, compensatory gene
with chemical inhibitors induces synthetic lethality and leads to cell death.
the ataxia telangiectasia and Rad3-related protein (ATR), a member of the DNA
repair machinery, in tumorswith defective TP53 [80, 86, 88] or KRAS genes [36]. As
potential synthetic lethal relationships are documented to be likely between DNA
repair genes and DNA replication genes [29, 39],ATR and DNA polymerases could
additionally represent promising synthetic lethal relationships. However, these
relationships remained so far insufficiently identified or characterized, and thus
should be further investigated.
1.3 Polymerases and the replication of DNA
The DNA polymerase (Pol) is an enzyme catalyzing the synthesis of DNAmolecules
from deoxyribonucleotides. Currently, at least 15 different polymerases are known
in eukaryotes [44], which can be divided into translesion DNA synthesis (TLS) and
replicative polymerases. TLS polymerases allow cells to complete replication de-
spite damaged DNA templates by promoting the replication complex through DNA
lesions, thus avoiding the halt of the replication process [93]. Alongwith their ca-
pability of DNA repair, TLS polymerases aremarked by features like lack of 3’–5’
exonuclease activity, low replication fidelity, the ability to copy a damaged DNA
strand, or catalyzing the polymerization using aberrant primer DNA ends [8]. Rep-
licative polymerases are responsible for the important process of replication of both
mitochondrial DNA (Polγ) and genomic DNA. The latter process is performed by
threemajor polymerases: the Polα-primase complex, Polδ, and Polε.
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The error-free replication of genomic DNA is a fundamental and essential biolog-
ical process of all living cells. Initiated during lateM- to earlyG1-phase, the origin
recognition complex, consisting of six subunits of DNA binding proteins, binds
to origins of replicationswithin the genome. Subsequently, it recruits other pro-
teins, including two copies of the hexameric minichromosomemaintenance (MCM)
complexwith a 3’→5’ polarity, and a yet dormant helicase activity to assemble the
pre-replication complex (pre-RC). In this state, the origins of replications are “li-
censed” for activation. Upon entry into S-phase, other essential replication proteins,
including the tetrameric GINS complex and Cdc45, are loaded onto the pre-RC, and
together with the separation of the double MCM complex into two single MCM
complexes activate the helicase activity. The two DNA helicases unwind the DNA
according to their 3’→5’ polarity in opposite directions, thus forming a replication
bubble, and the resulting single-strand DNA (ssDNA) is stabilized and protected
from degradation by being coatedwith RPA (Figure 3) [5, 12, 57].
The subsequent elongation step of the DNA replication is initiated by the Polα-
primase complex. This heterotetrameric protein consists of the two catalytic sub-
units PRIM1 and POLA1, which confer primase and polymerase activities, respec-
tively, and the two regulatory subunits PRIM2 and POLA2. Primase has the unique
ability to synthesize RNA primerwith an average length of 7–9 nucleotides de novo,
which are then furtherly elongated by Polα to form RNA-DNA hybrid primerwith a
fork
movement
3′
5′ 3′
5′
fork
movement
origin of
replication
RNA-DNA
primer
leading strand
lagging strand leading strand
lagging strand
PolδPolε
Polα-primase
complexDNA
helicase
RPA
Okazaki fragment
Figure 3 | Schematic illustration of a replication bubble
Starting at origins of replication, two DNA helicases unwind DNA in opposite directions
mediated by their 3’–5’ polarity, and thus creating a replication bubble. The ssDNA is coated
byRPA to stabilize and protect it fromdegradation,while the Polα-primase complex synthe-
sizes RNA-DNA hybrid primer. These serve as starting point for the continuous elongation
of the leading strand byPolε and the discontinuous elongation of the lagging strand byPolδ,
resulting inOkazaki fragments. The polymerases α-primase and δwere further investigated
in this dissertation and thus highlighted. Figuremodified fromRussell [85].
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length of 20–40 nucleotides [49, 77, 97], serving as starting point for the elongation
of the two separated DNA strands by the polymerases δ and ε. The similarity of
the moving direction between these two polymerases and the DNA helicase, i. e.
3’→5’ along the parental DNA strand, results in differences of elongation of the two
separated DNA strands. The synthesis of the new5’–3’ DNA strand is continuously,
as thepolymerasemoves in the samedirection as theDNAhelicase. ThisDNAstrand
is thus referred to as leading strand, andmainly, but not exclusively elongated by
Polε,whose catalytic subunit is encoded byPOLE [40]. The synthesis of the new3’–5’
DNA strand, however, is discontinuous, as the polymerase is forced tomove in the
opposite direction of the DNA helicase, and thus can only synthesize short DNA
strands, the so called Okazaki fragments. Hence, this DNA strand is referred to as
lagging strand, andmainly, but not exclusively elongated by Polδ. It consists of the
catalytic subunit POLD1 and the three regulatory subunits POLD2, POLD3, and
POLD4. Beside its polymerase activity, Polδ also has 3’–5’ exonuclease proofreading
activity, and is thus additionally involved in DNA repair synthesis [23, 67, 72].
As polymerases, especially the replicative DNA polymerases Polα-primase com-
plex, Polδ, and Polε, are responsible for both the fundamental processes of DNA
replication aswell as DNA repair, it is obvious that a proper functionality of these
proteins is crucial for the continuity of a cell’s viability. Therefore, any defects in
genes encoding for polymerases could result in accumulated genetic alterations and
a hence increased risk of tumorigenesis. In fact, defects in the TLS polymerase η
(encoded by the POLH gene), for example, result in a certain type of the xeroderma
pigmentosum diseasewith increased susceptibility to skin cancer [59]. Additionally,
multiple variants of uncertain significance (VUS)—these are genetically altered
alleles with unknown impact on the protein’s function or a potential pathogenic
outcome [82]—within the polymerases δ and ε have been identified in various can-
cers [7, 74, 94]. Asmentioned earlier, tumorswith defective tumor suppressor/ge-
nomemaintenance genes, including polymerases, might be treated by exploiting
their synthetic lethal interactions. However, the questionwhich genes might act
synthetically lethalwith certain polymerases has yet been insufficiently answered,
and thuswas investigated in this dissertation.
1.4 ATR and the DNA damage response
The genome is continuallyexposed to high levels of DNAdamage. Variousmolecular
mechanisms evolved tomaintain genome integrity, and the entirety of these mech-
anisms is known as DNA damage response (DDR). Key regulators of DDR are ATM
and ATR, bothmembers of the phosphoinositide 3-kinase-related kinase family.
ATM regulates—either directly or through its main effector kinase CHK2—various
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Figure 4 | Recruitment and activation of ATR
a | RPA coats ssDNA, which accumulates during stalled replication forks or certain DNA
repair mechanisms, to stabilize and protect it from premature degradation. b | The ability of
ATRIP,which is associatedwith ATR, to directly interactwith ssDNA-bound RPA localizes
ATR to sites of stalled replication forks or DNA damage. Additionally, RPA interactswith
RAD17, and thereby recruits the 9-1-1 complex. c | This complex then recruits TOPBP1,
which is thought to be the critical step in ATR activation. Activated ATR further participates
in DNA repair mechanism and, d | mediated byClaspin, also phosphorylates and thereby
activates CHK1, which is responsible for the induction of mechanisms involved in DNA
repair, cell cycle checkpoint activation, and replication origin firing. Figuremodified from
Rundle et al. [84].
signal transduction pathways includingDNA repair, cell cycle arrest, or gene expres-
sion, and is activated by the formation of DSB. The structural elements that result in
ATR activation are ssDNA. These accumulate during stalled replication forks or the
nucleoside excision repairmechanism, andare coatedbyRPAto stabilize andprotect
the ssDNA from premature degradation (Figure 4a). Through the direct interaction
between ATRIP,which is associatedwith ATR, and ssDNA-bound RPA, ATR is local-
ized to sites of replication stress or DNA damage. RPA additionally interactswith
RAD17 and thereby recruits the ring shaped DNA damage-specific RAD9, RAD1,
HUS1 complex (also called 9-1-1), which binds at junctions between ssDNA and
double-strand DNA (Figure 4b). The 9-1-1 complex then recruits TOPBP1,which is
thought to be the critical step in ATR activation. Activated ATR participates in DNA
repair mechanisms by targeting the Fanconi anemia proteins FANCD2 and FANCI
(comprehensively reviewed byNepal et al. [66]), and also by phosphorylating the HR
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regulatory protein BRCA1 (Figure 4c). The primary phosphorylation target of ATR,
however, is the kinase CHK1, for whose phosphorylation and thereby activation
Claspin is necessary. Activated CHK1 acts as intermediary, and induces various
reactions including DNA repair, cell cycle checkpoint activation, or replication ori-
gin firing (Figure 4d). In regard to DNA repair, CHK1 recruits and phosphorylates
the HR proteins RAD51 and BRCA2. By targetingWee1 togetherwith Cdc25A, or
Cdc25C, CHK1 is able to induce S-phase, or G2/M arrest, respectively, and thus
mediates cell cycle checkpoint activation. Additionally, the inhibition of replication
origin firing and thus the reduction of DNA replication rate under replication stress
orDNAdamaging conditions appears to be related to the initiation andmaintenance
of the S-phase arrest byCHK1 [4, 53, 84].
From a clinical perspective, the ATR pathway evolved as a promising target in
cancer therapy. As ATR pathway inhibitorswere demonstrated to effectively elim-
inate certain subsets of cancer cells [31, 98], several ATR [47, 78] and also CHK1
inhibitors [19, 89, 99] are currently investigated in clinical trials. Although the spe-
cific determinants of this therapeutic response are only insufficiently defined, it
is likely to be at least partly attributable to synthetic lethal relationships between
ATR and other DNA repair/genomemaintenance genes. Thus, such synthetic lethal
interactionswithATR should be comprehensively identified and characterizedwith
particular regard to polymerases.
1.5 Previous data and aims of this project
In a previous study from our laboratory, Hocke et al. [41] identified synthetic lethal
partners of ATR. Therefore, they used a small interfering RNA (siRNA) library tar-
geting 288 DNA repair genes in a cellularATR-knock-inmodel, which consisted of
ATR-proficientATR+/+ andATR-deficientATRs/s cells, of the colorectal cancer (CRC)
cell line DLD-1. By comparing the proliferation inhibitory effects on both ATR+/+
andATRs/s cells upon transfectionwith the respective siRNA, Hocke et al. [41]were
able to identify geneswhose depletion induced anATR-dependent proliferation in-
hibition. Consequently, these genes represented potential synthetic lethal partners
of ATR. POLD1, the catalytic subunit of Polδ, showed the strongest proliferation
inhibitory effects among those identified genes. Thus, thework of Hocke et al. [41]
started to additionally characterize the synthetic lethal relationship betweenATR
and POLD1. They showed that synthetic lethality and concomitantly the prolifer-
ation inhibitory effectswere inducible upon both genetic and chemical inhibition
of the ATR pathway in siRNA-mediated POLD1-depleted DLD-1 cells and various
other CRC cell lines. Mechanistically, they observed that POLD1-depletion inATR-
deficient cells did not impair cell cycle progression, but caused caspase-dependent
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apoptosis and increased DNA damage alongwith impaired DNA repair. In addition,
the synthetic lethal relationship between ATR and POLD1 [41] could have direct
clinical relevance, as multiple POLD1VUSwere recently reported in colorectal and
other cancers, however,with unknown significance to act as potential biomarkers
for a targeted therapywith ATR pathway inhibitors [7, 74, 94]. The knowledge and
correct interpretation of suchVUS is important especially for clinics and physicians,
as demonstrated by the example of BRCA1/2VUS,whose identificationmight in-
fluence important surgical decision-making for women [100]. Furthermore, the
previous screen also identified PRIM1, the catalytic subunit of primase of the Polα-
primase complex, as one potential synthetic lethal partner of ATR, inducing the
second strongest proliferation inhibitory effects upon inactivation of ATR. Thus,
this dissertationwas divided into two subprojects to investigate the synthetic lethal
relationships betweenATR and DNA polymerases, namely PRIM1 and POLD1 as
catalytic subunits of the Polα-primase complex and Polδ, respectively.
Thefirst subproject aimedtocharacterize thesynthetic lethal relationshipbetween
ATR and PRIM1, analogous to the characterization of the synthetic lethal relation-
ship betweenATR and POLD1 byHocke et al. [41], by addressing the following ques-
tions:
• is the previously observed synthetic lethal relationship between ATR and
PRIM1 verifiable?
• are the observations specific, or the result of clonal artifacts of the genetically
engineeredATR-knock-inmodel, or off-target effects of the siRNA targeting
PRIM1 (siPRIM1), respectively?
• is the proliferation inhibition also inducible in siPRIM1-transfected ATR-
proficient cells upon treatmentwith clinically relevant ATR pathway inhibi-
tors?
• is this synthetic lethal relationship betweenATR and PRIM1 also reproducible
in other cell lines derived from different tumor entities?
• whichmolecularmechanism underlies the synthetic lethal relationship be-
tweenATR and PRIM1?
The second subproject aimed to characterize the impact of specificPOLD1VUSon
the sensitivity of cancer cells to treatmentwith ATR pathway inhibitors. Therefore,
we used the CRISPR/Cas9 technique to establish a cellular POLD1-knockout (KO)
model in theCRCcell lineDLD-1,whichharbors fourheterozygousPOLD1VUS [28].
Subsequently, this modelwas used to answer the following questions:
• do specific POLD1 VUS have an impact on POLD1 gene function and ATR
pathway activation?
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• which POLD1 VUS increase the sensitivity of cancer cells to ATR pathway
inhibitors in vitro?
• which POLD1 VUS increase the sensitivity of cancer cells to ATR pathway
inhibitors in vivo?
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Methods
2.1 Cell culture
Thawing Frozen cellswere removed from liquid nitrogen storage, shortly thawed
at 37 °C, and added to their cultivation medium. The cell suspension was centri-
fuged at 300 g for 5minutes, and the cell pelletwas re-suspended in 1ml cultivation
medium, subsequently added to an appropriate amount of cultivationmedium in
a culture flask, and stored at 37 °C and 5%CO2. The following day, non-adherent
cellswere removed by replacing themediumwith fresh cultivationmedium.
Cultivation Cellswith a confluence of 90%were split by removing the cultivation
medium, washing with phosphate buffered saline (PBS), and detaching by using
0.05%Trypsin-EDTA for 5minutes at 37 °C. Detachmentwas stopped by adding
cultivationmedium twice of the amount of used Trypsin-EDTA. Cell suspension
was added in a ratio of 1:4 to 1:10 to a new culture flaskwith an appropriate amount
of cultivationmedium. The splitting procedurewas performed twice aweek, and
cell culture flaskswere stored at 37 °C and 5%CO2.
Freezing Detached cellswere centrifuged at 300 g for 5minutes. At least 1 × 106
cells were re-suspended in 1ml cultivation medium supplementedwith 10% di-
methyl sulfoxide (DMSO), and transferred to cryovials,whichwere primarily stored
by using a freezing container at -80 °C to achieve a cooling rate of -1 °C/minute. The
following day, cryovialswere transferred to liquid nitrogen for permanent storage.
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2.2 Transfection
The permanent or temporary introduction of foreign genetic material into eukary-
otic cells is called transfection. For this, a reverse liposome transfectionwas used
by enclosing the genetic materialwith the cationic, phospholipid-based transfec-
tion reagent, forming vesicles that canmergewith the cell membrane and hence
introducing the genetic material into the cells.
Plasmid DNA (1µg) or siRNA (10nM)were mixedwith the 0.5-fold amount of
the transfection reagent HiPerFect instead of the amount recommended by the
manufacturer. To allow stable formation of transfection complexes, the genetic
material and HiPerFectwere incubated inmedium free of fetal bovine serum (FBS)
for 20minutes at room temperature (RT). In the meantime, the appropriate cell
numberwas prepared and seeded inwells required for the respective assays. Trans-
fection complexeswere added directly after their formation to the freshly seeded
cell suspension and incubated at 37 °C and 5%CO2 for the required time period.
2.3 Establishment of an ATR re-expressing cell
clone
ATR-deficient ATRs/s cells were seeded in 6-well plates and co-transfected as de-
scribedwith vectors pcDNA3-ATRWT, conferring neomycin resistance, and pLKO-
U6-Tet-on-shNT5E-965, conferring puromycin resistance, in a ratio of 10:1. The co-
transfectionwas necessary, asATRs/s cells alreadyharbor a neomycin resistance [42].
The transfection complex containing cultivationmediumwas replacedwith puro-
mycin containing cultivationmedium for selection of stably transfected cells. After
threeweeks of selection, selected cellswere allowed to grow in single cells colonies
for twoweeks, and consecutively screened by immunoblotting for high expression
of ATR as compared toATRs/s cells. The clonewith the highest expression of ATR
was chosen for further experiments.
2.4 Western blot
Total protein extraction Cellswere centrifuged at 300 g for 5minutes, the super-
natantwas discharged, and the pellet re-suspended and incubated for 20minutes in
lysis buffer, containing the two phosphatase inhibitors Na3VO4 and phenylmeth-
ylsulfonyl fluoride (PMSF) aswell as the protease inhibitor “ProteaseArrest”. The
suspensionwas centrifuged at 10 000 rpm for 2minutes, and the supernatantwas
used in a Bradford protein assay to determine the protein concentration. This assay
containedCoomas sie Brilliant BlueG-250, a red dye that turns into a blue state after
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complexingwith proteins. The blue intensitywas photometrically analyzed, and
protein concentrationwas estimated by using a straight calibration line of bovine
serum albumin (BSA). Finally, dithiothreitol (DTT) at a final concentration of 0.1M,
and sodium dodecyl sulfate (SDS) loading bufferwere added to the protein lysate
to break disulfide bridges and to denature proteins to their linear shape, as this
structure is necessary for the subsequent electrophoretic migration.
Immunoblotting Empty buffer was added to the protein samples to reach an
equivalent volume for each sample, before theywere heated for 5minutes at 95 °C.
Sampleswere loaded on polyacrylamide gels in running buffer and allowed to elec-
trophoreticallymigrate through thegels. After separation, proteinswere transferred
to a polyvinylidene fluoride (PVDF) membranewith the tank blot technique and
transfer buffer. To avoid unspecific binding of antibodies, the blottedmembrane
was blockedwith blocking buffer for 1 hour at RT, and then incubated overnight at
4 °C in fresh blocking buffer, containing the primary antibody directed against the
target protein (Table 6). The antibody solutionwas removed, and themembranewas
washedwith TBST, incubated for 1hour at RT in fresh blocking buffer containing
a horseradish peroxidase (HRP) conjugated secondary antibody (Table 7) targeted
against the primary antibody, and subsequentlywashed. By treating themembrane
with a substrate containing luminol, which is oxidated by the HRP conjugated sec-
ondary antibody, a chemiluminescence reaction was induced and detected by a
ChemoCam. The intensity of the chemiluminescence signals correlatedwith the
protein amount and hencewas used to detect and quantify proteins. Afterwards,
themembranewas incubated for 1 hour at RT in blocking buffer containing a HRP
conjugated antibody targeting β-Actin, serving as loading control to ensure the pro-
tein amounts of all loaded samples to be equivalent. Finally, the membrane was
washed and the amount of β-Actinwas detected and quantified using the luminol
containing substrate as described above.
2.5 Cell proliferation assay
Cell proliferation assayswere used to quantify the amount of surviving cells after
treatmentwith various drugs at multiple concentrations. Depending on the exper-
imental design, one of the following three procedures was conducted: cells were
seeded in 96-well plates (600 ATR+/+ and ATRs/s cells each, 800 ATRresc cells, 1800
POLD1+/+, POLD1+/+ control (ctrl), and POLD1R689W/- cells each, or 1500 POLD1+/-
cells) and treated the following daywith the respective drug for 120hours; cells
were seeded in 96-well plates (600ATR+/+ andATRs/s cells each, or 800ATRresc cells)
and transfected as described for 144hours; cellswere seeded in 6-well plates (1×105
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DLD-1andSW480cells each, 7×104RKOcells, or6.6×104 PaTu8988t cells) and trans-
fected as described for 96 hours before transfected cellswere transferred to 96-well
plates (600 DLD-1 cells, 1000 SW480 cells, 800 mock-transfected cells and non-
transfected cells (NTC) of RKO and PaTu 8988t each, or 2000 siPRIM1-transfected
cells of RKO and PaTu 8988T each) and treated the following daywith the respective
drug for 120hours. Following each incubation period at 5%CO2 and 37 °C,medium
was removed, and cellswerewashedwith PBS and lysed for 30minuteswith H2O
supplementedwith 0.2% SYBR® Green I, which intercalatedwith the DNA of lysed
cells. In this state it emitted a green fluorescent dye that was detected by a plate
reader. The amount of fluorescent signals correlatedwith the amount of cells in
eachwell. The surviving fractionwas calculated as compared to untreated control
samples.
2.6 Flow cytometry
Flow cytometry allows the characterization of certain cell populations by optically
analyzing single cells, which are labeledwith fluorochrome conjugated antibodies.
Light emitted in thisway is detected and quantified, allowing the identification and
analysis of cell populationswithin a heterogeneous cell suspension. For thiswork,
flow cytometrywas used to analyze the cell cycle profile.
Cellswere seeded and transfected as described in 6-well plates. After 144hours,
cellswere collected,washed in PBS, and centrifuged at 300 g for 5minutes. The cell
pelletwas re-suspended in a PI staining solution and incubated at 4 °C overnight as
previously described [68]. The cell cycle distributionwas quantified by using a flow
cytometer. At least 20 000 gated events per samplewere analyzedwith the FlowJo
software.
2.7 Immunocytochemistry
Immunocytochemistry is a technique tomicroscopically assess cellular structures,
visualized byfluorochrome conjugated antibodies targeting the respective proteins.
For this dissertation, nuclear focus formation at sites of DNA damagewas analyzed.
Cellswere seeded and transfected as described on sterile coverslips in 6-well plates.
After incubation for 120hours, the cultivationmediumwas removed, and cellswere
washedwith PBS and fixedwith 3.7% formaldehyde for 10minutes. After a short
incubation in ice-cold methanol (-20 °C), cells werewashed in PBS for 5minutes,
incubated in permeabilization solution for 10minutes, and afterwards in blocking
solution for 30minutes. The primaryantibody (Table 6), diluted in blocking solution,
was applied overnight at 4 °C. Cellswerewashed in blocking solution three times for
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5minutes, before secondary antibody (Table 7), diluted in blocking solution and con-
jugatedwith a fluorochrome,was applied for 2 hours at RT.Then, slideswerewashed
with blocking solution three times for 5minutes andmounted on object slides, using
a mounting medium supplemented with 4’,6-diamidino-2-phenylindole (DAPI),
a fluorescent DNA stain. Object slides were microscopically analyzed, and focus
formation of at least 70 cellswas quantified using the ImageJ software.
2.8 Gene knockout with CRISPR/Cas9
CRISPR/Cas9 is part of the prokaryotic immune system to confer resistance to
foreign genetic material, and is also basis of amolecular biological technique that
enables a highly specific and easy to achieve genome editing. The Cas9 endonucle-
ase (Figure 17) is associatedwith a guide RNA (gRNA), which harbors a sequence
targeting the gene of interest. It binds a protospacer adjacent motif (PAM), and—if
the gRNA sequence hybridizes perfectlywith the target DNA sequence—introduces
a DSB upstream the PAM. This DSB can either be repaired by non-homologous end
joining via introducing indel mutations, or by HR. The latter repair mechanism
introduces specific sequences into the genome if a repair template is provided. Also,
a repair template allows to generate a gene KO by disrupting the Cas9-binded exon
structure.
For this project, a CRISPR/Cas9 POLD1 knockout kitwas used, containing two
Cas9 plasmids (targeted sequence of gRNA1 TGCCCCCAAAGCGGGCCCGT and
gRNA2GGGATGATGATGATGCACCT, respectively), one Cas9 plasmidwith a scram-
bled sequence as control and a repair templatewith a floxed puromycin resistance
gene togetherwith a left homology arm (LHA) and right homology arm (RHA) re-
gion (Figure 18). In exon 2a of the POLD1 locus Cas9 induced a DSB, allowing the
integration of the repair template due to the LHA and RHA regions. This repair
templatewas used to repair the DSBvia HR, resulting in a disrupture of POLD1, and
thus causing a KO (Figure 5).
Cellswere seeded in 6-well plates and co-transfected as describedwith one of the
three Cas9 plasmids and the repair template for 72 hours. The transfection complex
containingmediumwas replacedwith puromycin containingmedium for selection
of stably transfected cells. Selected cells were allowed to grow in single cell colonies
for two weeks and genotyped, using the primers #1–#4 (Table 8). Heterozygous
clones show two PCR products, one representing the KO allele (∼1000 bp) and the
other one representing the intact wild type (WT) allele (1656 bp). To engineer homo-
zygous KO clones, heterozygous cloneswere first transfectedwith a Cre vector for
72 hours to remove the floxed puromycin resistance (PuroR) gene. Single cell colon-
ies with removed PuroR gene were genotyped using primers #5 and #6 (Table 8).
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PuroRPGKpromoterTurboGFP
loxP loxP
exon 2a
exon 2a exon 3
gRNA2
PAM2 (CGG)
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gRNA1
PAM1 (GGG)
Figure 5 | Disruption of POLD1 exon 2a by integrating a repair template
Schematic overviewof the targeting procedure, displaying CRISPR/Cas9-mediated inte-
gration of the repair template in exon 2a of the POLD1 locus. Abbreviations | gRNA: guide
RNA; LHA: left homology arm; PAM: protospacer adjacent motif; PuroR: puromycin resis-
tance; RHA: right homology arm.
Colonieswithout the PuroR genewere transfected againwith one of the three Cas9
plasmids, and the repair template as described.
2.9 Polymerase chain reaction
Preparation of genetic templates RNA or DNA was isolated from cells, fol-
lowing the manufacturer’s instructions of the RNA/DNA purification kits, and
concentrationsweremeasured using a nano drop. For amplification, RNAwas re-
verse transcribed into complementaryDNA (cDNA), using a reverse transcription
kit. A mastermixwas prepared, including 1× buffer, mix of deoxyribonucleotide
triphosphate (dNTP) (each 1mM), 0.2 µM oligo(dT) primer, 2 units of reverse tran-
scriptase, and 0.5–1µg RNA per reaction, added to RNase-freewater. The reverse
transcriptionmixwas incubated at 37 °C for 1–2hours.
Amplification and gel electrophoresis Genomic DNA or newly synthesized
cDNA served as template for the amplification of the DNA fragments of interest.
A mastermixwas prepared, including 1× buffer, mix of dNTP (each 0.2mM), for-
ward and reverse primer (each 0.5 pmol, Table 8), 1.25 units of Taq polymerase, and
100–200ng DNA template per reaction, added to nuclease-freewater. After ampli-
fication in a thermal cycler (all PCR programs and conditions are described in the
appendix, Figure 19 andTable 10), 1× DNA loading dyewas added to the PCRmix.
For electrophoretic separation, sampleswere loaded on a 1% agarose gel (prepared
in TBE buffer) supplementedwith a UV sensitive dye, that intercalatedwith DNA
and hence visualized the amplified PCR products on a UV transilluminator.
Methods 17
Sequencing Sequencing of the amplified DNAwas performed byGATC Biotech,
utilizing Sanger’s chain-terminationmethod. Normal dNTPs togetherwith dide-
oxyribonucleotide triphosphates (ddNTPs), of which eachwas conjugatedwith a
different fluorochrome,were used in a PCR-similar reaction. Whenever a ddNTP
instead of a dNTPwas used by the polymerase, the elongation of the DNA strand
terminated, leaving DNA fragments of different sizes, each of themwith a certain
terminalfluorescent signal. Arrangedbysizevia capillarygel electrophoresis, a laser
detected the fluorochomes and depicted all fluorescent signals in a chromatograph,
allowing computational sequence analysis. Samples were prepared as asked by
GATC Biotech, and sequencing primers are listed in Table 8.
2.10 DNA fiber assay
TheDNAfiber assay is a technique to analyze the replication process bymicroscopic-
ally quantifying length and structure of single DNA fibers. These experimentswere
kindly performed by Prof. Dr. Kerstin Borgmann and Alexandra Zielinski from
the Lab of Radiobiology& Experimental Radiooncology of the UniversityMedical
Center Hamburg-Eppendorf in Hamburg.
Exponentially growing cellswere labeledwith 25μM 5-chloro-2′-deoxyuridine
(CldU) followed by 250μM5-iodo-2′-deoxyuridine (IdU) for 30minutes each. For
analysis of fork stability, cellswere treatedwith 2mMhydroxyurea (HU) for 4 hours,
or irradiatedwith 6Gy between both labels. Labeled cellswere harvested, and their
DNAfiber spreadswere prepared and stained as previously described [69, 75]. In
short, labeled cell suspensionwas placed on object slides and lysed, before object
slideswere tilted 15°, allowing DNA fibers to spread. After air drying DNA fibers
werefixed anddenaturedwithHCl, before incubated inprimaryantibodies. Amono-
clonal rat anti-BrdU antibodywas used to detect CldU, and a monoclonal mouse
anti-BrdUwas used to detect IdU. Goat anti-rat and goat anti-mouse antibodies—
conjugatedwith AlexaFluor 555 or AlexaFluor 488, respectively—were used as sec-
ondary antibodies, andDNAfiberswere examined using anAxioplan 2 fluorescence
microscope. CldU and IdU tracksweremeasured, using the ImageJ software, and
micrometer valueswere converted into kilobases. At least 100 forkswere analyzed.
Different classes of labeled trackswere classified: red-green (ongoing replication),
red (stalled forks), and green (2nd pulse origins). Labeled trackswere counted using
the ImageJ software, and at least three independent experimentswere performed.
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2.11 Mouse xenograft tumor model for in vivo
experiments
Themouse xenograft tumormodel enables the analysis of the impact of pharmaceu-
tical drugs on induced tumors in a living organism. As tumors are induced by cells
of different species, a strong immunological reactionwould normally be provoked
in mice. To avoid this, mice with a genetically induced athymic phenotype and a
subsequent strong decrease of T cells are used.
To calculate the required group sizewe used 5% for the error of the first kind and
0.9 for the statistical power, resulting in an effect size of 1.5with estimated tumor
volumes of 1200mm3 for the control group, 900mm3 for the treatment group, and
an estimated standard deviation of 200mm3. According to G*Power—a program
recommended by the regional commission of Gießen to calculate the group size—
these values resulted in a size of ninemice per group. All animal experimentswere
performed according to the guidelines of the German law for animal life protection
and approved by the regional commission of Gießenwith the file numberG44/2017.
Fourweek old female NMRI-Foxn1nu/nu nudemicewere purchased and allowed to
acclimate for twoweeks in an incubatorwith constant temperature and humidity.
Xenograft tumors were induced by subcutaneously injecting 106 cells of DLD-1
POLD1+/+ or POLD1R689W/- cells, respectively, both suspended in PBS. Twoweeks
after injectionmicewithapalpable tumorwere randomlydivided into twogroups for
each cell clone and the ATR inhibitor AZD6738 at a dose of 50mg/kg or the vehicle
solution alone were administered by gavage once daily for five consecutive days,
followed by two days of no administration. This application schedulewas conducted
for four weeks (Figure 6), as long as the immediate no-go criteria, i. e. a tumor
diameterof ≥1.5 cm, ora lossof bodyweightof ≥20%(equivalent toabodycondition
score of 1),were notmet. During this period,micewereweighed and scored for their
body condition daily. Furthermore, the tumor sizewasmeasured twice aweekwith
treatment with
AZD6738/vehicle no treatment
day 1
subcutaneous
injection
tumor
excision
15 22 29 36 43
Figure 6 | Schematic depiction of the application schedule
Cancer cells were subcutaneously injected on day 1, and allowed to grow for two weeks.
Starting on day 15, micewere treated eitherwith AZD6738 orwith vehicle for five consecu-
tive days, followed by two dayswithout treatment. This application schedulewas conducted
for fourweeks before on day 43 tumorswere excised.
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calipers and the calculated tumor volume (V = x ⋅ y2 ⋅ 0.5, with x = longest diameter,
y= shortest diameter) on day one of the inhibitor/vehicle application was set as
reference to calculate the percentage change of tumor volume.
2.12 Statistical analyses
All statistical analyses were performed using Prism 5, and data are presented as
mean ±SD. Surviving fractions of proliferation assays were calculated by curve
fittingwith nonlinear regression. A two-tailed, unpaired Student’s t test or a two-
way ANOVAwith Bonferroni post-test were used for statistical interpretation. P
values of P <0.05 (*), P <0.01 (**), or P <0.001 (***) were considered statistically
significant.
20
3
Material
3.1 Cell lines and other organisms
The human CRC cell lines DLD-1, SW-480, and RKO were purchased from the
Leibniz Institute DSMZ (Braunschweig, Germany) or the AmericanType Culture
Collection (LGC Standards, Wesel, Germany). The human pancreatic cancer cell
line PaTu 8988twas kindly provided byHans-Peter Elsässer (Philipps-University
Marburg, Germany). The DLD-1 cell clone ATRs/s was kindly provided by Fred
Bunz (JohnHopkins University, Baltimore, MD, USA), and has been characterized
previously [30, 31, 42]. NMRIFoxn1nu/nu nude mice were purchased from Charles
River Laboratories (Wilmington, MA, USA).
3.2 Equipment, software, and expendable materials
Table 1 | Equipment
Equipment Company
Air flow cabinet (Uniprotect)
EHRETLabor- und
Pharmatechnik
Balance (EMB 500-1) KERN& SOHN
Biological safety cabinets
(MSC-Advantage™)
Thermo Fisher Scientific
Biosafety changing station (interACTIVE) Tecniplast
Centrifuge (Heraeus™Megafuge™ 8) Thermo Fisher Scientific
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Table 1 | Equipment (continued)
Equipment Company
Centrifuge (Heraeus™Multifuge 3SR+) Thermo Fisher Scientific
Centrifuge (Micro Star 17) VWR
ChemoCam
INTAS Science Imaging
Instruments
Feeding tube, 20 ga×38mm Instech Laboratories
Flow cytometer (BD FACSCanto II) BD Biosciences
Freezer -80 °C (HERAfreeze™) Thermo Fisher Scientific
Freezing container (Nalgene®Mr. Frosty) Sigma-Aldrich
Incubation bath GFL
Incubator (Heracell™ 240i) Thermo Fisher Scientific
Microplate photometer (Multiskan FC) Thermo Fisher Scientific
Microscope (Axioplan 2) Carl Zeiss
Microscope (Axiovert 200M) Carl Zeiss
Microscope Olympus
Multichannel pipette
(Pipet-Lite XLS L-300)
Mettler-Toledo
Nano drop ND-1000 Peqlab Biotechnologie
Neubauer chamber Plan Optik
Pipetboy INTEGRA Biosciences
Pipettes Gilson
Plate reader (Victor3 V) PerkinElmer
Refrigerator -20 °C, 4 °C Liebherr
Thermal cycler (T100™Thermal Cycler) Bio-Rad Laboratories
Thermomixer 5436 Eppendorf
UV transilluminator
Intas Science Imaging
Instruments
Table 2 | Software
Software Company
Creative Suite 5 Adobe Systems
FlowJo v10 FlowJo
GraphPad Prism 5 GraphPad Software
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Table 2 | Software (continued)
Software Company
ImageJ 1.49v
Wayne Rasband,
National Institutes of Health, USA
MendeleyDesktop v1.17.13 Mendeley
MiKTEX 2.9 Christian Schenk
Office 2013 Microsoft
SnapGene®Viewer v4.1.4 GSL Biotech
TEXworks v0.6.2
Jonathan Kew, Stefan Löffler,
Charlie Sharpsteen
Table 3 | Expendable material
Expendablematerials Company
6-well plate Greiner Bio-One
96-well plate F-bottom Greiner Bio-One
Cell culture flask (T25, T75) Sarstedt
Coverslips (Menzel-Gläser 24 × 24mm) Thermo Fisher Scientific
Cryotubes (Cryo.s™) Greiner Bio-One
Microtest Plate 96-well, F Sarstedt
Object slides (Superfrost®Plus) Thermo Fisher Scientific
Pipette tips (1000µl) Sarstedt
Pipette tips (10 µl, 200 µl) Sarstedt
Pipette tips (multichannel pipette) Mettler-Toledo
PVDFmembrane
(Immobilon®-P transfer membrane)
Merck
Reaction tubes (0.5ml, 1.5ml, 2ml) Sarstedt
Reaction tubes (15ml, 50ml) Sarstedt
Reaction tubes PCR (Multiply-Pro cup 0.2ml) Sarstedt
Serological pipettes (2ml) Greiner Bio-One
Serological pipettes (5ml, 10ml, 25ml, 50ml) Sarstedt
Syringe 1ml (NORM-JECT®) Henke-Sass,Wolf
Tube 5ml, 75 × 12mm, PS Sarstedt
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3.3 Chemicals, reagents, solutions, and media
Table 4 | Chemicals and reagents
Substance Company
1,2-Bis(dimethylamino)ethane (TEMED) Sigma-Aldrich
1,3-Propanediol Sigma-Aldrich
4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES)
Carl Roth
5-Chloro-2′-deoxyuridine (CldU) Sigma-Aldrich
5-Fluorouracil (5-FU) Sigma-Aldrich
5-Iodo-2′-deoxyuridine (IdU) Sigma-Aldrich
Acrylamide (Rothiphorese® Gel 30) Carl Roth
Agarose Carl Roth
Ammonium persulfate (APS) Sigma-Aldrich
Aqua dest. B. Braun
AZD6738 (in vitro) MedKoo Biosciences
AZD6738 (in vivo) AdooQ Bioscience
Boric acid Carl Roth
Bovine serum albumin (BSA) Thermo Fisher Scientific
Bradford solution (Roti®-Nanoquant) Carl Roth
Bromophenol blue Sigma-Aldrich
Carboplatin UniversityHospital Marburg
Cre vector Santa Cruz Biotechnology
CRISPR/Cas9 genome knockout kit OriGene Technologies
Deoxyribonucleotide triphosphate
(dNTP) mix
Thermo Fisher Scientific
Dimethyl sulfoxide (DMSO) Carl Roth
Dithiothreitol (DTT) SERVA Electrophoresis
DNA gel loading dye Thermo Fisher Scientific
DNA ladder (GeneRuler 1 kb) Thermo Fisher Scientific
DNA purification kit
(QIAmp® DNAMini Kit)
Qiagen
Ethylene glycol-bis(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid (EGTA)
Sigma-Aldrich
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich
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Table 4 | Chemicals and reagents (continued)
Substance Company
Fetal bovine serum (FBS) Thermo Fisher Scientific
Formaldehyde 3.7% Otto Fischar
Glycerol Carl Roth
HiPerFect Qiagen
Hydroxyurea (HU) Sigma-Aldrich
Luminol substrate
(Clarity™Western ECL substrate)
Bio-Rad Laboratories
Luminol substrate
(Western Lightning® Ultra)
PerkinElmer
LY2603618 Selleckchem
Methanol Sigma-Aldrich
MK-8776 Selleckchem
Mountingmedium
(Roti®-Mount FluorCare DAPI)
Carl Roth
Mytomycin C (MMC) Sigma-Aldrich
Na3VO4 Sigma-Aldrich
Na4P2O7⋅10 H2O Sigma-Aldrich
NaCl Carl Roth
NaF Sigma-Aldrich
Oligo(dT) primer biomers
Oxaliplatin UniversityHospital Marburg
Phenylmethylsulfonyl fluoride (PMSF) Sigmal-Aldrich
Phosphate buffered saline (PBS) Thermo Fisher Scientific
Polymerase (GoTaq® G2 DNA Polymerase) Promega
Powderedmilk Carl Roth
Primer (PCR/sequencing) biomers/GATC Biotech
Propidium iodide (PI) Sigma-Aldrich
Protease inhibitor (ProteaseArrest) G-Bioscience
Protein ladder (PageRuler™) Thermo Fisher Scientific
Protein ladder
(Spectra™multicolor high range)
Thermo Fisher Scientific
Puromycin InvivoGen
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Table 4 | Chemicals and reagents (continued)
Substance Company
Reverse transcription kit
(Omniscript® RTKit)
Qiagen
RNA purification kit (RNeasy®Mini Kit) Qiagen
RPMI 1640 Thermo Fisher Scientific
siPOLD1
(5’-CGGGACCAGGGAGAATTAATA-3’)
Qiagen
siPRIM1
(5’-AACCACAGATCAAATACTTCA-3’)
Qiagen
Sodium citrate Sigma-Aldrich
Sodium dodecyl sulfate (SDS) Carl Roth
SYBR®Green I Lonza
Tris Carl Roth
Triton X-100 Carl Roth
Trypsin Thermo Fisher Scientific
Tween 20 Sigma-Aldrich
UV sensitive dye
(HDGreen Plus DNA Stain)
Intas Science Imaging
Instruments
VE-822 MedKoo Biosciences
Vector pcDNA3-ATRWT
Addgene
(donated byAziz Sancar [45])
Vector pLKO-U6-Tet-on-shNT5E-965
Stephan A. Hahn,
Laboratory of Molecular Oncology,
University Bochum, Germany
Table 5 | Media, buffer, and solutions
Medium Ingredient Concentration
Blocking buffer
Powderedmilk 5%
TBST pure
Blocking solution
BSA 2%
Permeabilization solution pure
Cultivationmedium
FBS 10%
RPMI 1640 pure
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Table 5 | Media, buffer, and solutions (continued)
Medium Ingredient Concentration
Empty buffer
PBS 70%
SDS loading buffer 30%
Lysis buffer
EGTA 1mM
Glycerol 10%
HEPES 50mM
Na3VO4 2mM
Na4P2O7 · 10H2O 10mM
NaCl 150mM
NaF 100mM
PMSF 1mM
ProteaseArrest™ 1%
Triton X-100 1%
Permeabilization solution
TBS pure
Triton X-100 0.5%
PI staining solution
Propidium iodide 50µg/ml
Sodium citrate 0.1%
Triton X-100 0.1%
Running buffer
Glycine 190mM
Tris 25mM
SDS 0.1%
SDS loading buffer, pH 6.8
Bromophenol blue 1.9mM
Glycerol 40%
H2O 50%
SDS 0.5%
Tris 63nM
Separating gel buffer, pH 8.8
SDS 0.4%
Tris 1.5M
Separating gel solution, 10%
Acrylamide 33%
APS 0.02%
H2O pure
Separating gel buffer 25%
TEMED 0.2%
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Table 5 | Media, buffer, and solutions (continued)
Medium Ingredient Concentration
Stacking gel buffer, pH 6.8
SDS 0.4%
Tris 0.5M
Stacking gel solution
Acrylamide 4.8%
APS 0.03%
H2O pure
Stacking gel buffer 25%
TEMED 0.3%
TBE buffer
Boric acid 89mM
EDTA 2mM
Tris 89mM
TBS buffer, pH 7.6
NaCl 150mM
Tris 20mM
TBSTbuffer, pH 7.6
TBS pure
Tween 20 0.1%
Transfer buffer, pH 8.3
Glycine 190mM
Tris 20mM
SDS 0.1%
Vehicle solution
1,3-propanediol 40%
DMSO 10%
H2O 50%
3.4 Antibodies and primer
Table 6 | Primary antibodies
Target (clone) Species Dilution Clonality Company
ATR (N-19) goat 1:500 poly
Santa Cruz
Biotechnology
Caspase 3 rabbit 1:1000 poly
Cell Signaling
Technology
Caspase 8 (1C12) mouse 1:1000 mono
Cell Signaling
Technology
Material 28
Table 6 | Primary antibodies (continued)
Target (clone) Species Dilution Clonality Company
Caspase 9 (H-170) rabbit 1:500 poly
Santa Cruz
Biotechnology
Cdc25A (5H51) mouse 1:1000 mono
Santa Cruz
Biotechnology
CHK1 (G4) mouse 1:500 mono
Santa Cruz
Biotechnology
cleaved Caspase 3
(Asp175)
rabbit 1:1000 poly
Cell Signaling
Technology
Cyclin A (H-432) rabbit 1:1000 poly
Santa Cruz
Biotechnology
PARP rabbit 1:1000 poly
Cell Signaling
Technology
pCHK1 (Ser345)
(133D3)
rabbit 1:1000 mono
Cell Signaling
Technology
POLD1 (A-9) mouse 1:500 mono
Santa Cruz
Biotechnology
PRIM1 (8G10) rat 1:1000 mono
Cell Signaling
Technology
Wee1 (B-11) mouse 1:1000 mono
Santa Cruz
Biotechnology
β-Actin (HRP
conjugated) (AC-15)
mouse 1:40 000 mono Sigma-Aldrich
γH2AX (Ser139)
(20E3)
rabbit 1:200 mono
Cell Signaling
Technology
Table 7 | Secondary antibodies
Target Species Conjugate Dilution Company
goat IgG donkey HRP 1:20 000
Santa Cruz
Biotechnology
mouse IgG bovine HRP 1:10 000
Santa Cruz
Biotechnology
rabbit IgG goat Alexa Fluor 488 1:500
Thermo Fisher
Scienfitic
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Table 7 | Secondary antibodies (continued)
Target Species Conjugate Dilution Company
rabbit IgG goat HRP 1:10 000
Santa Cruz
Biotechnology
rat IgG goat HRP 1:10 000
Santa Cruz
Biotechnology
Table 8 | Primer
Primer Orientation Localization Sequence (5’ - 3’)
#1 forward
POLD1,
upstream LHAa
GTGAGAGAGCACACACACGAC
#2 reverse
repair template,
GFP
TAGGTGCCGAAGTGGTAGAAGC
#3 forward
repair template,
spacer region
TCTCTTGATTCCCACTTTGTGGT
#4 reverse
POLD1, down-
streamRHAb
CAGATCAACGCTCCAAGCAC
#5 forward
repair template,
LHA
GAGGTGTCTCCGGTCAGAAC
#6 reverse
repair template,
PuroRc
GAGGCCTTCCATCTGTTGCT
#7 forward
POLD1NCSd,
upstream exon 13
CCCAGACCCTGACGACTTGG
#8 reverse
POLD1NCS, down-
stream exon 13
TGGGAGTGGGGAGAAAAAGTG
#9 forward
POLD1NCS,
upstream exon 17
TGCGTGAATTAGCACAAGGC
#10 reverse
POLD1NCS, down-
stream exon 17
GGACCAATTGCTCAAGCCAC
#11 forward
POLD1NCS,
upstream exon 18
TCCGCATGATTCTCTCCCCG
#12 reverse
POLD1NCS, down-
stream exon 18
GTGGCTAATGCCAACGGGAC
#13 forward
POLD1,
exon 2a
GGGCCTCTGGGATGATGATG
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Table 8 | Primer (continued)
Primer Orientation Localization Sequence (5’ - 3’)
#14 reverse
POLD1, down-
stream exon 18
ACCGCATCGATATCTCCCAG
#15 forward
POLD1,
upstream exon 13
GTATCATGGACCCCGACGTG
#16 reverse
POLD1, down-
stream exon 13
GCCCCTCAAAGGGTACTACG
#17 forward
POLD1,
upstream exon 17
CTGTGTTACACCACGCTCCT
#18 reverse
POLD1, down-
stream exon 18
CAACCTGGTCACTGCCTCAC
#S1 forward
POLD1NCS,
upstream exon 2a
TCAGAACCTCCACCAAG
#S2 forward
POLD1NCS,
upstream exon 13
ACTTCCTTCTCCTGCTC
#S3 forward
POLD1NCS,
upstream exon 17
TGTGCAGTGCACAGTAC
#S4 forward
POLD1NCS,
upstream exon 18
GTTCGGACGTCAGATGATC
#S5 forward
POLD1,
upstream exon 13
CTCCTACACGCTCAATG
#S6 forward
POLD1,
upstream exon 17
AGATCCTGGAGAACCTG
a left homology arm
b right homology arm
c puromycin resistance
d non-coding sequence
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Results
4.1 Characterizing the synthetic lethal relationship
between ATR and PRIM1
The application of an siRNA library revealed a to date unknown synthetic lethal
relationship between ATR, a central regulator of the DNA damage response, and
PRIM1, the catalytic subunit of primase of the Polα-primase complex [41]. As ther-
apy approaches based on synthetic lethal interactions gain in importance for an
individualizedand targeted treatment [55], the relationshipbetweenATRandPRIM1
could represent anovel concept for cancer therapy. Thus, the aimof this first subpro-
jectwas to verify and further characterize the synthetic lethal relationship between
ATR andPRIM1, assessing the impact of PRIM1depletion on cancer cells upon either
genetic or chemical disruption of ATR function. In addition,we also investigated the
underlyingmolecular mechanism regarding cell cycle progression and apoptosis.
4.1.1 Verifying the synthetic lethality of ATR and PRIM1
For the identification of the synthetic lethal relationship betweenATR and PRIM1
a well-defined ATR knock-in model was used [41], consisting of ATR-proficient
(ATR+/+) andATR-deficient (ATRs/s) cells of the human CRC cell line DLD-1 [42]. To
exclude artifacts due to clonal variation of this ATR knock-in model we first es-
tablishedATR re-expressing cells (ATRresc) and confirmed the subtotal ATR protein
depletion inATRs/s and the ATR protein re-expression inATRresc cells via immuno-
blotting (Figure 7a). We confirmed the previously described increased sensitivity of
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Figure 7 | Verification of the synthetic lethality between ATR and PRIM1 in DLD-1
cells
a | ATR protein quantification inATR+/+,ATRs/s, andATRresc cells via immunoblottingwith
β-Actin serving as loading control. b | MMC sensitivity assessment of ATR+/+,ATRs/s, and
ATRresc cells via proliferation assay 120hours after treatment . c | PRIM1 protein quanti-
fication via immunoblotting 120hours after siPRIM1 transfectionwith β-Actin serving as
loading control. d | Proliferation inhibition assessment of ATR+/+,ATRs/s, andATRresc cells via
proliferation assay 144hours after siPRIM1 transfection. e | ST1926 sensitivity assessment
of ATR+/+ andATRs/s cells via proliferation assay 120hours after treatment. Data inform-
ation | All data are presented asmean ±SD. Experimentswere performed independently
(n = 4 for figure part b; n = 3 for figure parts d + e)with each data point reflecting triplicate
wells. Immunoblots were performed independently twice (figure part a) or three times
(figure part c), respectively, and representative results are shown. Statistical significance
(*P <0.05, **P <0.01, ***P <0.001, n.s. = not significant) refers to siPRIM1 vs. NTC if not
depicted otherwise, andwas calculated using a two-tailed, unpaired Student’s t test (figure
part d) or a two-wayANOVAwith Bonferroni post-test (figure part b + e).
ATRs/s cells to ICL agents [30] by treatmentwithmitomycin C (MMC). This effectwas
partially reversible inATRresc cells (Figure 7b).
To verify the synthetic lethal relationship betweenATR and PRIM1we depleted
PRIM1 inATR-deficient cells byusingan siRNAtargetingPRIM1 (siPRIM1, Figure 7c).
Similarly toMMC,we confirmed the previously reported proliferation inhibition of
ATRs/s cells upon PRIM1 depletion [41] and observed partial rescue effects uponATR
re-expression (Figure 7d). To exclude off-target effects of siPRIM1we also assessed
the sensitivity of ATRs/s cells to ST1926, a chemical inhibitor of Polα [1, 33, 37]. As
there are no chemical inhibitorsyet available to directly target primase, and primase
is complexedwith Polα,we thought a Polα inhibitor to be suitable to preliminarily
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exclude off-target effects. In fact,we observed an increased sensitivity of ATRs/s cells
to ST1926 as compared toATR+/+ cellswith an IC50 ratio of 3 (Figure 7e).
In conclusion, by extending thewell-definedATR knock-inmodelwithATR re-
expressing cellswe excluded clonal variation, and verified the previously reported
proliferation inhibitory effects onATR-deficient cells either upon siRNA-mediated
PRIM1 depletion, or upon chemical Polα inhibition to beATR specific.
4.1.2 Sensitizing various cancer cell lines to ATR and CHK1
inhibitors through PRIM1 depletion
To assess a potential translational medical exploitability of the synthetic lethal
relationshipbetweenATRandPRIM1weanalyzedwhether thedetrimental effects of
PRIM1 depletion on genetically inducedATR-deficient cellswere similarly inducible
in ATR-proficient cells upon chemical inhibition of ATR. Therefore, we treated
ATR+/+ NTC aswell as mock- and siPRIM1-transfected DLD-1 cells (Figure 8a)with
the selective and clinically investigated ATR inhibitors AZD6738 andVE-822 [47,
78]. The sensitivity of DLD-1 cells to treatment with these ATR inhibitors was
significantly increaseduponPRIM1depletion as compared toNTCwith IC50 ratios of
14 and 9, respectively (Figure 8b). Additional treatmentwith the selective inhibitors
LY2603618 andMK-8776 [19, 89, 99], targeting ATR’s major downstream effector
kinase CHK1, achieved similar effects with IC50 ratios of 9 and 10, respectively
(Figure 8c). To exclude a general and unspecific drug hyper-sensitivity mediated
by PRIM1 depletion we treated cells with common chemotherapeutics including
MMC, 5-fluorouracil (5-FU), and oxaliplatin, and observed no significant PRIM1-
dependent effects (Figure 8d).
DLD-1 cells are known to bemicrosatellite-instable [3, 48]. Therefore, to exclude
confounding artifacts, and at the same time to generalize our data beyond one
single cell line we analyzed the effects of PRIM1 depletion on additional cancer
cell lines upon treatmentwith ATR and CHK1 inhibitors. We used NTC aswell as
mock- and siPRIM1-transfected cells of the human CRC cell lines SW480 and RKO,
which are microsatellite-stable and -instable, respectively, as well as the human
microsatellite-stable pancreatic cancer cell line PaTu 8988t [26] (Figure 9a). Similar
to DLD-1 cells, we observed an increased sensitivity of SW480, RKO, and PaTu
8988t cells to treatmentwith ATR inhibitors (IC50 ratios ranging from 4 to at least
13, Figure 9b) and also CHK1 inhibitors (IC50 ratios ranging from 3 to at least 26,
Figure 9c) upon PRIM1 depletion as compared to NTC.
In summary,we showed that the detrimental proliferation inhibitory effectswere
also inducible inATR-proficient cells using chemical inhibitors specifically targeting
ATR and CHK1 independently of themicrosatellite stability status, and applicable
tomultiple cell lines derived from different tumor entities.
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Figure 8 | Sensitization of DLD-1 cells to ATR and CHK1 inhibitors upon PRIM1 de-
pletion
a | PRIM1 knockdown confirmation via immunoblotting 96hours after transfectionwith
β-Actin serving as loading control. b | Sensitivity assessment of PRIM1-depleted cells as
compared to NTC andmock-transfected cells via proliferation assay 120hours after treat-
mentwith ATR inhibitors, c | CHK1 inhibitors, and d | common chemotherapeutics. Data
information | All data are presented as mean ± SD. Experimentswere performed independ-
ently (n = 3)with each data point reflecting triplicatewells. Immunoblotswere performed
independently for each proliferation assay, and representative results are shown. Statistical
significance (*P < 0.05, **P < 0.01, ***P < 0.001) refers to siPRIM1vs. NTC, andwas calculated
using a two-wayANOVAwith Bonferroni post-test.
4.1.3 Assessing the molecular mechanism of the synthetic
lethal relationship between ATR and PRIM1
After analyzing the detrimental effects of ATR and PRIM1 depletion on different
tumor cell lines, we investigated the molecular mechanism underlying this syn-
thetic lethal relationship. Comparison of the cell cycle profiles of ATR+/+ andATRs/s
cells expectably revealed a constitutive increase of the G2/M fraction alongwith
a slight decrease of the S-phase fraction in ATRs/s cells (Figure 10a) due to their
loss of DNA damage checkpoint responses [17]. Interestingly, the additional deple-
tion of PRIM1 induced a significant increase of the S-phase fraction exclusively
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Figure 9 | Sensitization of RKO, SW480, and PaTu 8988t cells to ATR and CHK1 inhib-
itors upon PRIM1 depletion
a | PRIM1 knockdown confirmation via immunoblotting 96hours after transfectionwith
β-Actin serving as loading control. b | Sensitivity assessment of PRIM1-depleted cells as
compared to NTC andmock-transfected cells via proliferation assay 120hours after treat-
mentwithATR inhibitors and c | CHK1 inhibitors. Data information | All data arepresented
asmean ±SD. Experimentswere repeated independently (n = 3 forVE-822-, LY2603618-,
and MK-8776-treated SW480 cells; n = 4 for AZD6738-treated SW480 cells; n = 5 for all
experimentswith RKO and PaTu 8988t cells) with each data point reflecting triplicatewells.
Immunoblotswere performed independently for each proliferation assay, and representa-
tive results are shown. Statistical significance (*P <0.05, **P <0.01, ***P <0.001) refers to
siPRIM1 vs. NTC, andwas calculated using a two-wayANOVAwith Bonferroni post-test.
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Figure 10 | Impairment of cell cycle progression in ATRs/s cells upon PRIM1 deple-
tion
a | Cell cycle profile assessment of DLD-1ATR+/+ andATRs/s cells via FACS analysis 144 hours
after siPRIM1 transfection. b | S-phase fraction of the cell cycle profile in detail. c +d | Pro-
tein quantification in DLD-1 ATR+/+ and ATRs/s cells via immunoblotting 144hours after
siPRIM1 transfectionwith β-Actin serving as loading control. Percentage protein change
of PRIM1-depleted cells was normalized to NTC of DLD-1 ATR+/+ and ATRs/s cells. Data
information | All data are presented asmean ± SD. Experiments assessing the cell cycle pro-
filewere repeated independently (n = 4). Immunoblotswere performed independently three
times, and representative results are shown. Statistical significance (*P <0.05, n.s. = not
significant)was calculated using a two-tailed, unpaired Student’s t test.
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inATRs/s cells (Figure 10b). To identify the responsiblemediators of this effectwe
quantified the cell cycle protein levels of CHK1;Wee1, a key regulator of cell cycle
progression [21, 58]; aswell as Cdc25A and Cyclin A, mediators of the G1/S progres-
sion (Figure 10c + d). CHK1 proteinwas activated through phosphorylation upon
PRIM1 depletion. However, this effect appeared to be ATR-independent. The latter
is consistentwith a previous report of a sufficient CHK1 phosphorylation inATRs/s
cells [42]. Furthermore,we observed a PRIM1-dependent regulation of the kinase
Wee1, i. e. an upregulation inATR+/+ and a downregulation inATRs/s cells. Similarly,
also the phosphotaseCdc25Awas upregulated inATR+/+ anddownregulated inATRs/s
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Figure 11 | Induction of apoptosis in ATRs/s cells upon PRIM1 depletion
a | Sub-G1 fraction of the cell cycle profile (Figure 10a) in detail. b | Protein quantification
in DLD-1ATR+/+ andATRs/s cells via immunoblotting 144hours after siPRIM1 transfection
with β-Actin serving as loading control. c | γH2AX quantification in DLD-1 ATR+/+ and
ATRs/s cells via immunocytochemistry 120hours after siPRIM1 transfection. Data informa-
tion | All data are presented as mean ± SD. Experimentswere repeated independently (n = 4
for the assessed sub-G1 fraction; n = 3 for the γH2AX foci formation). Immunoblotswere
performed independently (n = 2 for caspase 3, PARP, and caspase 9; n = 3 for caspase 8), and
representative results are shown. Statistical significancewas calculated using a two-tailed,
unpaired Student’s t test (**P < 0.01, n.s. = not significant).
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cells. In contrast, Cyclin A appeared to be slightly upregulated inATRs/s cells upon
PRIM1 depletion as compared to PRIM1-depletedATR+/+ cells, but this effect did not
reach statistical significance.
As the cell cycle profiles also revealed a significant increase of the sub-G1 fraction
in PRIM1-depletedATRs/s cells (Figures 10a + 11a)we next investigated the protein
levels of the central apoptosis mediators in ATR+/+ and ATRs/s cells upon PRIM1
depletion (Figure 11b). Consistentwith the sub-G1 datawe observed the cleavage
of caspase 3, the main effector protease of apoptosis, along with the cleavage of
its substrate PARP only in PRIM1-depletedATRs/s cells. Similarly, the indicator of
extrinsic apoptosis caspase 8was cleaved PRIM1-dependently inATRs/s cells, while
caspase 9, an indicator of the intrinsic apoptosis pathway, appeared to be cleaved
unspecifically. We additionally investigated the accumulation of DNA damage to
test its potential contribution to the observed apoptotic effects by quantifying the
formation of γH2AX, a surrogatemarker for DNADSBs [83] (Figure 11c). AsATR is a
centralmediator of DDR,ATR-deficientATRs/s cells expectablydisplayed a slight but
not significant increase of γH2AX foci as compared toATR+/+ cellswith no further
augmentation upon PRIM1 depletion.
In summary,we showed that the detrimental effects of PRIM1 depletion inATRs/s
cells is in part attributable to S-phase impairmentwith concomitantWee1 down-
regulation and a subsequent activation of the extrinsic apoptotic pathwaywithout
evidence of increased DNA damage accumulation.
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4.2 Assessing the impact of POLD1 variants of
uncertain significance to treatment with ATR
pathway inhibitors
Apart from PRIM1 also POLD1, the catalytic subunit of Polδ, displays synthetic
lethal interactionswithATR, which has been previously described [41]. This inter-
action could be of clinical relevance as various POLD1 variants have been identi-
fied in colorectal and other cancers [7, 74, 94]. However, the significance of these
variants as potential biomarkers for the targeted treatment of tumors with ATR
inhibitors remains enigmatic. Thus, the aim of this second subprojectwas to estab-
lish a POLD1-KOmodel to enable the prediction of the impact of certain variants
on the therapeutic response to ATR pathway inhibitors by using various read-outs.
Establishing thismodel,we characterized four POLD1 variants in regard to their
impact on the sensitivity to ATR pathway inhibitors in vitro and in vivo. Additionally,
we assessed their impact on the DNA damage response.
4.2.1 Establishing heterozygous POLD1-knockout clones by
using CRISPR/Cas9
With recent publications reporting various POLD1 variants in familial cases of
CRC [7, 74, 94], and the identified synthetic lethality of ATR and POLD1 [41] we
assessedwhether such variantswere clinically exploitable for potential treatment
with inhibitors targeting the ATR pathway. We therefore used the CRISPR/Cas9
technique to establish a POLD1-KO in the CRC cell line DLD-1,which harbors four
heterozygous POLD1 variants [28]. We genotypedmultiple single cell colonies and
obtained twodistinctheterozygousPOLD1-KOclones (termedg1-2andg2-1) aswell
as a POLD1+/+ ctrl clone,whichwas transfectedwith a scrambled gRNA (Figure 12a).
The immunoblot of POLD1+/- g1-2 and g2-1 cells revealed no changes in POLD1
protein expression as compared to POLD1+/+ parental and ctrl cells (Figure 12b).
To generate a homozygous POLD1-KOwe first excised the PuroR cassette in g1-2
and g2-1 cell clonesmediated by the Cre/loxP recombinase (Figure 12c), and then
targeted the second allele. However, despite multiple targeting rounds we were
unable to establish a homozygous POLD1-KO cell clone.
We confirmed the four heterozygous POLD1 variants G10V, R506H, R689W, and
S746I, which were previously reported in DLD-1 cells [28], in our POLD1+/+ par-
ental cells by genome sequencing (Figure 13, upper panel). As the allele specific
localization of these variants remained unknown, we used mRNA sequencing to
demonstrate that the intact POLD1 allele of the heterozygous cell clone g1-2 exhib-
ited only the R689Wvariant, thus being termed POLD1R689W/- (Figure 13, middle
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Figure 12 | Generation of a DLD-1 POLD1-knockout via CRISPR/Cas9
a | Detection of the POLD1-KO and -WTalleles in POLD1+/+ parental and ctrl cells aswell as
in POLD1+/- g1-2 and g2-1 cells via PCR. b | Protein quantification in POLD1+/+ parental and
ctrl cells aswell as in POLD1+/- g1-2 and g2-1 cells via immunoblottingwith β-Actin serving
as loading control. c | Detection of the Cre/loxP-mediated excision of the PuroR cassette in
POLD1+/- g1-2 and g2-1 cells via PCR.
panel). The intact POLD1 allele of the heterozygous cell clone g2-1 exhibited the
three other POLD1 variants G10V, R506H, and S746I (POLD1G10V, R506H, S746I/-, Fig-
ure 13, lower panel). However, according to the data obtained later (no functional
significance of POLD1G10V, POLD1R506H, and POLD1S746I), and for conveniencewe
retrospectively termed this cell clone here POLD1+/-.
4.2.2 Characterizing the functional impact of various POLD1
variants
After generating heterozygous POLD1-KO cell clones,which exclusively expressed
either POLD1R689W or POLD1G10V, R506H, S746I, we assessed the impact of these vari-
ants on POLD1 function. As defects in DNA replication lead to the compensatory
activation of DNA repair pathways [38], the functional impairment of POLD1 could
be expected to cause compensatory activation of the ATR pathway [41]. Thus, we
assessed protein and phosphorylation levels of CHK1, the major effector kinase
of ATR, in the respective cell clones harboring different POLD1VUS.We observed
a strong constitutive CHK1 phosphorylation exclusively in POLD1R689W/- but not
in POLD1+/- and POLD1+/+ cells, an effect which was qualitatively comparable to
the effects of siRNA-mediated subtotal POLD1 depletion (Figure 14a). These data
indicated that only POLD1R689W but not POLD1G10V, POLD1R506H, or POLD1S746I
had a functional relevance. Therefore, we next assessed the impact of POLD1R689W
on DNA replication upon treatment with ionizing radiation (IR) or HU via DNA
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Figure 13 | Allele-specific localization of POLD1 variants in DLD-1 cells
Localization of POLD1 variants in POLD1+/+ parental cells aswell as the POLD1+/- g1-2 and
g2-1 cell clones via genome andmRNA sequencing.
fiber assays (Figure 20). We assessed the elongation rate, which correlateswith the
replication pace; 2nd pulse origins, which represent new replication origin firing
of dormant origins; and stalled replication forks as marker for the physiological
response to replication stress. The constitutive overall elongation ratewas slightly
higher in POLD1R689W/- than in POLD1+/+ cells. Upon IR treatment, however, the
elongation rate decreased only in POLD1R689W/- cells, but remained unchanged in
POLD1+/+ cells (Figure 14b). Furthermore,we observed that HU treatment induced a
stronger decrease of 2nd pulse origins in POLD1+/+ than in POLD1R689W/- cells (Fig-
ure 14c). Consistently, stalled replication forkswere only increased in POLD1+/+ but
not in POLD1R689W/- cells upon HU treatment (Figure 14d).
In summary, our data indicated that of the four previously described POLD1
variants in DLD-1 cells only POLD1R689W had an impact on gene function, as com-
pensatoryATRpathwayactivation and impairment of DNA replication, respectively,
were exclusively observable in POLD1R689W/- cells.
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Figure 14 | Functional characterization of POLD1R689W in DLD-1 cells
a | Protein quantification in POLD1+/+, POLD1R689W/-, and POLD1+/- cells via immunoblot-
ting in a constitutive state as well as 120hours after siPOLD1 transfection with β-Actin
serving as loading control. b | Quantification of the elongation rate, c | 2nd pulse origins, and
d | stalled replication forks in POLD1+/+ and POLD1R689W/- cells via DNAfiber assay upon
IR or HU treatment. Data information | All data are presented asmean ± SD. Experiments
were performed independently (n = 3)with at least 100 DNA fibers analyzed in each experi-
ment. Immunoblotswere performed independently (n = 3), and representative results are
shown. Statistical significancewas calculated using a two-tailed, unpaired Student’s t test
(n.s. = not significant).
4.2.3 Assessing the impact of POLD1R689W on the sensitivity of
DLD-1 cells to ATR pathway inhibitors in vitro
Wefirst assessed the impact of POLD1R689W on the cellular sensitivity to ATR and
CHK1 inhibitors in vitro. Compared to POLD1+/+ parental and ctrl cells, we observed
only in POLD1R689W/- but not in POLD1+/- cells an increased sensitivity to the se-
lective ATR inhibitors AZD6738 andVE-822 [47, 78] with IC50 ratios of 11 and 6,
respectively (Figure 15a). Similarly, onlyPOLD1R689W/- but not POLD1+/- cells dis-
played an increased sensitivity to the selective CHK1 inhibitors LY2603618 and
MK-8776 [19, 89, 99] with IC50 ratios of 5 and 4, respectively (Figure 15b). To ex-
clude a general and unspecific drug hyper-sensitivitymediated by POLD1R689Wwe
treated cellswith common chemotherapeutics includingMMC, 5-FU, carboplatin,
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Figure 15 | Sensitization ofDLD-1 cells toATR andCHK1 inhibitors in vitromediated
by POLD1R689W
Sensitivity assessment of POLD1R689W/- cells as compared to POLD1+/- and POLD1+/+ par-
ental and ctrl cells 120hours after treatmentwith a | ATR inhibitors, b | CHK1 inhibitors,
and c | common chemotherapeutics. Data information | All data are presented as mean
± SD. Experimentswere repeated independently (n = 3 for the treatmentwithATR inhibitors,
MMC, and carboplatin; n = 4 for the treatmentwith CHK1 inhibitors, 5-FU, and oxaliplatin)
with each data point reflecting triplicatewells. Statistical significance (*P < 0.05, **P < 0.01,
***P <0.001) refers to siPRIM1 vs. NTC, andwas calculated using a two-wayANOVAwith
Bonferroni post-test.
and oxaliplatin, and observed no POLD1R689W-dependent differences in prolifera-
tion (Figure 15c).
In summary, our in vitro data showed that only the POLD1 variant R689Wbut not
G10V, R506H, or S746I sensitized DLD-1 cells specifically to inhibitors targeting
ATR or CHK1, and that this proliferation inhibitory effect is not caused by a general
and unspecific drug hyper-sensitivitymediated by POLD1R689W.
4.2.4 Assessing the impact of POLD1R689W on the sensitivity of
DLD-1 cells to the ATR inhibitor AZD6738 in vivo
Wenext extended our in vitro data byusing amurine xenograft tumormodel to assess
the sensitivity of POLD1+/+ and POLD1R689W/- cells to the ATR inhibitor AZD6738 in
vivo. Treatment of micewith vehicle or AZD6738 [50mg/kg]waswell tolerated, as
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lossof bodyweight in thebeginningof this experimentdidnot exceed10%, and later
even normalized to the initial bodyweight, thus remaining in the animalwelfare
guidelines (Figure 16a). Regarding tumor size, we observed the strongest growth
in vehicle-treated POLD1+/+ tumors (Figure 16b) nearly quadrupling their original
size (Figure 16c). While the R689W-mediated impairment of POLD1 alone or the
ATR-inhibition byAZD6738 alone only slightly decreased tumor size and growth,
the combined impairment of POLD1 and inhibition of ATR strongly decelerated
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Figure 16 | Sensitization of DLD-1 cells to the ATR inhibitor AZD6738 in vivo medi-
ated by POLD1R689W
a | Bodyweight change assessment of vehicle- or AZD6738-treatedmice during the four-
week treatment. b | Weight assessment of POLD1+/+ or POLD1R689W/- tumors fourweeks
after constant treatment with vehicle or AZD6738. c | Growth assessment of POLD1+/+
or POLD1R689W/- tumors during the four-week treatmentwith vehicle or AZD6738. Data
information | All data are presented as mean ±SD with six mice in the vehicle-treated
POLD1+/+ tumor group, six mice in the AZD6738-treated POLD1+/+ tumor group, fivemice
in the vehicle-treated POLD1R689W/- tumor group, and fourmice in the AZD6738-treated
POLD1R689W/- tumor group.
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tumor growth as illustrated by AZD6738-treated POLD1R689W/- tumors not even
doubling their original size during the entire observation period (Figure 16b + c).
In summary, these data showed that the POLD1R689W variant sensitized DLD-1
cells specifically to the ATR inhibitor AZD6738 also in vivo. Togetherwith the in vitro
data these observations are therefore consistentwith our functional data regarding
CHK1 phosphorylation and impaired DNA replication. However, the in vivo data are
limited by the fact, thatwe could only analyze fourmice in the important group of
AZD6738-treated POLD1R689W/- tumors, due to the unexpected low tumor take rate.
The in vivo data presented here are thus preliminary, representing distinct trends,
butwithout a statistical significance yet. Hence, further verification in additional
xenograft in vivo experiments is mandatory.
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Discussion
5.1 Inactivation of PRIM1 function sensitizes cancer
cells to ATR and CHK1 inhibitors
As the principle of synthetic lethality offers newapproaches for an individualized
and targeted cancer therapywith reduced side effects [46, 70], we here verified and
characterized the previously identified synthetic lethal relationship between the
DNA damage sensing protein ATR and the catalytic subunit of primase of the Polα-
primase complex PRIM1 [41].
5.1.1 Verifying the synthetic lethality
Initially, we usedATRs/s cells of the human CRC cell line DLD-1,whichwere genet-
ically engineered to homozygously harbor the ATR “Seckel” variant A2101G [73],
resulting in a subtotal ATR protein depletion with increased sensitivity to DNA
ICL agents but no significant effect on cell growth or viability [30, 31, 42, 101]. As
this subtotal ATR protein depletionmimicked the incomplete pharmacological in-
hibition of ATRmore closely than a complete and lethalATR-KO [17], this model
proved to be ideally suited for our experiments. Additionally,we established anATR
re-expressing rescue cell clone to exclude clonal variation as a confounding artifact.
By demonstrating the proliferation inhibition of ATRs/s cells upon siRNA-mediated
PRIM1 depletion, an effectwhichwas partly reversible uponATR re-expression,we
confirmed the synthetic lethal relationship between ATR and PRIM1. To exclude
potential off-target effects of siPRIM1 it would be necessary to treatATRs/s cellswith
a PRIM1 inhibitor. However, selective PRIM1 inhibitors remain to be developed. To
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overcome this problem nonetheless, we treatedATRs/s cellswith ST1926, a chemical
inhibitor of Polα of the Polα-primase complex [1, 33, 37]. As Polα functionally de-
pends on the preceding RNA primer synthesis by primase [49, 77, 97], a functional
hierarchyof the Polα-primase complexmaybe deducedwith primase being epistatic
to Polα. Thus, we assumed that targeting downstream components might cause
similar effects as targeting primase. Indeed,we observed similar proliferation inhib-
ition of ATRs/s cells upon treatmentwith ST1926, thus indicating off-target effects
of siPRIM1 to be unlikely. Additionally, these data demonstrated due to the func-
tional hierarchyof the Polα-primase complex that not onlyprimase, i. e. its catalytic
subunit PRIM1, but also the functional downstream Polα, i. e. its catalytic subunit
POLA1, could potentially represent a novel target for therapeutic approaches using
ATR inhibitors.
5.1.2 In vitro validation
As the chemical inhibition of ATR is known to eliminate certain subsets of cancer
cells, which is partly attributable to synthetic lethality,we next assessedwhether
the proliferation inhibitory effects on PRIM1-depleted cellswith a genetically in-
ducedATR deficiencywere also elicitable in PRIM1-depleted,ATR-proficient cells
with a chemically induced ATR deficiency. We therefore used clinically relevant
inhibitors targeting ATR [47, 78] and its main effector kinase CHK1 [19, 89, 99]. In
fact, both ATR and CHK1 inhibitors decreased proliferation of DLD-1 cells upon
PRIM1depletion. Importantly,wewere able to generalize our data bydemonstrating
similar results in two additonal CRC cell lines, SW480 and RKO, aswell as in the
pancreatic cancer cell line PaTu 8988t. As these cell lines exhibit bothmicrosatellite
stability and instability, respectively,we showed that our data are independent of
themicrosatellite instability status. Therefore, inactivated PRIM1 in cancers could
represent a predictive biomarker for their sensitivity to ATR and CHK1 inhibitors.
5.1.3 Mechanistic insights
Mechanistically,we demonstrated an increased S-phase fraction inATRs/s cells upon
PRIM1 depletion and a concomitant upregulation of phosphorylated CHK1 and
downregulation of Cdc25A, thus indicating cell cycle arrest during S-phase [63, 76].
However, the virtually undiminished protein levels of Cyclin A in PRIM1-depleted
ATRs/s cells rather suggested an S-phase stasis than a classical S-phase arrest [9].
This assumption is consistentwith Hurley and colleagues, describing that ionizing
radiation of ATRs/s cells led to a prolonged S-phasewhich closely resembled S-phase
stasis [42]. The induced S-phase stasis in cells simultaneously depleted of bothATR
and PRIM1might thus represent an unresolvable replication catastrophe.
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Besides cell cycle impairment and perhaps evenmore importantly, apoptosis con-
tributed to the PRIM1-dependent proliferation inhibitory effects, as demonstrated
by the increased sub-G1 fraction and the cleavage of the common apoptosis effector
enzymes caspase 3 and PARP exclusively in PRIM1-depletedATRs/s cells. Addition-
ally, the simultaneous ATR- and PRIM1-dependent cleavage of caspase 8 but not
of caspase 9 hinted at an extrinsic rather than an intrinsic apoptosis induction [13].
Typically, extrinsic apoptosis is predominantlymediated by death receptors [13].
Additionally, downregulation of Wee1, as observed in our experiments inATRs/s cells
upon PRIM1-depletion, also leads to apoptosis through increased surface expres-
sion of death receptors [34, 91]. As the accumulation of DNA damage might also
contribute to apoptosis, we furthermore quantified γH2AX foci formation,which
serves as surrogatemarker for DNA damage in terms of DSBs [83]. Interestingly,we
did not observe an increase of DSBs, and thus excluded their contribution to apop-
tosis. Therefore, apoptosis induced by the downregulation of Wee1might represent
a protective cellular response to the precedingly induced replication catastrophe in
ATR-deficient cells upon PRIM1-depletion.
5.1.4 Role of PRIM1 in cancer
Little is known about the prevalence of genetic alterations of PRIM1 in cancer. The
amplification of a large region including the PRIM1 gene locus was reported in
osteosarcoma [104], and upregulation of PRIM1 gene expressionwas reported in
cancers of lung [102] and breast [54]. Besides these few reports about altered gene
expression, only 0.2% of around 35 000 tested tumor samples showed variants in
PRIM1 according to the Catalogue Of SomaticMutations In Cancer (COSMIC). For
comparison, the COSMIC database lists around 150000 and more than 240000
tested tumor samples for the intensively characterized tumor suppressor gene TP53
and the proto-oncogeneKRAS, respectively [87]. This insufficiencyof data regarding
PRIM1 alterations in cancer illustrates the need to further characterize the role of
PRIM1 in cancer, as its potential as novel target for future therapeutic approaches
in defined small subsets of tumors still remains poorly defined.
5.1.5 Future studies
The synthetic lethal relationship betweenATR and PRIM1was recently identified
and in this dissertation for the first time characterized. To validate the clinical sig-
nificance of this relationship future studies aremandatory. In our experimentswe
used siRNA to deplete PRIM1. Due to the lack of selective PRIM1 inhibitorswewere
not able to directly exclude off-target effects of siPRIM1, which should be further
evaluatedwhen suitable chemical compounds are developed. Instead,we indirectly
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excluded off-target effects by using ST1926, a selective Polα inhibitor [1, 33, 37].
Besides ST1926, other chemical compounds were reported to selectively inhibit
Polα including dehydroaltenusin [56, 62], demethoxydehydroaltenusin [51], and
depeptide alcohols [50]. As the efficacy of these inhibitors on the proliferation of
ATRs/s cells is unknown, this should be further investigated, especiallywith a poten-
tial clinical application inmind. Furthermore, the ST1926-mediated proliferation
inhibition of ATRs/s cells indicated that the inhibition of any compound of the Polα-
primase complex togetherwith impairment of ATR could induce synthetic lethality.
Thus, the potential synthetic lethal relationship betweenATR and POLA1, the cata-
lytic subunit of Polα, should be verified using siPOLA1 and further characterized
similar to PRIM1, as these data could facilitate a novel concept for ATR-deficient
tumors being treated with inhibitors targeting the Polα-primase complex. This
future characterization and the here demonstrated in vitro characterization of the
synthetic lethality betweenATR and PRIM1 could then also be extended to the in vivo
setting, e. g. a murine xenograft tumormodel as proof of principle prior to clinical
trials. Beside the abovementioned identification of PRIM1 variants in tumors, also
POLA1 variants (0.9% of around 35000 tested samples) and ATR variants (2.3%
of around 51000 tested samples) were identified in tumors [87]. With regard to
the later discussed impact of the POLD1R689W variant on the cellular sensitivity to
ATR pathway inhibitors, the systematical evaluation of prevalence as well as the
identification and characterization of gene variants of the Polα-primase complex
and alsoATR should be the aim of future studies.
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5.2 Sensitization of DLD-1 cancer cells to ATR
pathway inhibitors through the POLD1R689W
variant
By screening an siRNA library we previously identified ATR to act synthetically
lethal not onlywith PRIM1, but alsowith POLD1, the catalytic subunit of Polδ [41].
While VUS in POLD1 have been recently identified in colorectal and other can-
cers [7, 74, 94], their significance as potential biomarkers for a targeted therapy
with inhibitors of the ATR pathway remained unknown. Yet, the identification and
characterization of VUS is of importance as illustrated by the example of BRCA1/2.
Patientswith identified pathogenic BRCA1/2 variants are recommended for consid-
eration of prophylactic surgeries due to their BRCA1/2VUS-mediated higher risk of
tumorigenesis [100]. Thus,we here established a cellular POLD1-KOmodel system
to determine the pathogenicity of individual POLD1VUS.
5.2.1 POLD1-knockout
The CRC cell line DLD-1 harbors the four heterozygous POLD1 variants G10V,
R506H, R689W, and S746I [28] with unknown allele localization. To establish a
POLD1-KOmodel system and to identify the variant’s allele specific localizationwe
applied theCRISPR/Cas9 technique in order to separatelydisrupt eachPOLD1 allele.
Following genome/mRNA sequencing, we demonstrated that G10V, R506H, and
S746I are localized together on one POLD1 allele, while R689W is isolated on the
second POLD1 allele. The obtained heterozygous KO clones therefore exclusively
expressed either POLD1G10V, R506H, S746I (termed POLD1+/-) or POLD1R689W (termed
POLD1R689W/-), respectively. By generating KO cell clones with this exclusive ex-
pression of certain variantswe achieved an ideal model system for the functional
characterization of POLD1 VUS. Despite multiple targeting rounds, wewere not
able to establish a homozygous POLD1-/- clone, indicating POLD1 to be an essential
gene in cancer cells. This hypothesis is further supported by a study byUchimura
et al. [92], demonstrating in a murine KO model that POLD1 is also essential for
embryonic development.
5.2.2 Mechanistic insights
In our system, onlyPOLD1R689W butnot POLD1G10V, R506H, S746I hadan impact ongene
function as shown by the compensatory activation of the ATR pathway and the con-
comitantly strong increase of CHK1 phosphorylation exclusively in POLD1R689W/-
cells. Because CHK1 is activated in response to DNA damage [76], our data indi-
cated that the POLD1R689W variant might increase endogenous DNA damage. Con-
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sistentwith this hypothesis, its Saccharomyces cerevisiae analog POLD1R696Wwas re-
ported to cause a catastrophic genomic instability and a mutator phenotype in
yeast [18, 60, 61]. With the data regarding the POLD1R689W-mediated increased sen-
sitivitytoATRpathwayinhibitors inmind, theassessmentof CHK1phosphorylation
could therefore provide a useful biomarker to identifyPOLD1-VUSwhich induce
an increased sensitivity to ATR inhibitors in a clinical setting [53].
To mechanistically assess the impact of POLD1R689W during DNA replication
more accuratelywe also applied DNA fiber assays. The observed constitutive in-
crease of elongation rate in POLD1R689W/- cells could be attributable to a reduction
of nucleotide selectivity caused by the POLD1R689W variant [60, 61]. In contrast,
IR-treatment led to a decreased elongation rate in POLD1R689W/- cells as compared
to POLD1+/+ cells. This could be explained byDNA damage overload caused by ad-
ditional induction of extrinsic DNA damage in cells that already harbor amutator
phenotypemediated by POLD1R689W, ultimately leading to irreversible instability
of DNAfibers. Of note, the R689Wvariant is located in the polymerase active do-
main of POLD1,while no variantwithin the exonuclease domainwas identified in
POLD1R689W/- cells. Thus, the proofreading function can be expected to be intact, as
has been previously shown for POLD1R696W, the yeast analog of POLD1R689W [18].
However, elevated levels of nucleotides, as caused by the POLD1R689W variant [60],
result in a switch from exonuclease to polymerase activity [32]. In combinationwith
thenucleotide selectivitydefectsmediatedbyPOLD1R689W [60, 61] this could explain
themutator phenotype despite an intact proofreading exonuclease domain. Unex-
pectedly, POLD1R689W did not have an impact on the ongoing replication process,
even upon treatment with HU, which inhibits the ribonucleotide reductase [103],
resulting in decreased levels of nucleotides, and thus a blocked replication process.
This could be explained by the alreadymentioned POLD1R689W-induced increase of
nucleotide levels [60], consecutively antagonizing the effects of HU.
5.2.3 In vitro and in vivo validation
Wenext assessed the impact of POLD1R689W on the cellular sensitivity to ATR path-
wayinhibiting chemical agents in vitro, using clinicallyrelevant inhibitors of ATR [47,
78] and CHK1 [19, 89, 99]. In fact, both ATR and CHK1 inhibitors decreased prolif-
eration specifically of POLD1R689W/- but not POLD1+/- cells. Importantly, no signific-
ant proliferation differenceswere observable between these cells upon treatment
with common chemotherapeutics, excluding a general and unspecific drug hyper-
sensitivitymediated by POLD1R689W. As a proof of principle prior to clinical trials,
we further tested the effects of the ATR inhibitor AZD6738 on POLD1R689W/- cells
in amurine xenograft tumormodel in vivo. Only the simultaneous impairment of
both POLD1 and ATR (AZD6738-treated POLD1R689W/- tumors) caused a trend of
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decelerated tumor growth,while the impairment of either POLD1 alone (vehicle-
treated POLD1R689W/- tumors) or ATR alone (AZD6738-treated POLD1+/+ tumors)
had no discernible effects on tumor growth as compared tovehicle-treated POLD1+/+
tumors.
5.2.4 Comparison with theoretical prediction tools
We compared our data defining the functional significance of the investigated
POLD1 variantswith data fromvarious pathogenicity prediction tools, including
PON-P2, a machine learning-based classifier, which groups variants into patho-
genic, neutral, orunknownclasses, basedonrandomforestprobabilityscore [71,79];
PolyPhen-2, calculating the naive Bayes posterior probability of a variant’s impact
on protein function to be possibly/probably damaging or benign (non-damaging) [2,
20]; PROVEAN,which uses an alignment-based score to discriminate between dele-
terious andneutral effects onprotein function [14, 43]; andMutationAssessor, calcu-
lating a functional impact score byusing evolutionaryconservation patterns [16, 81].
According to these prediction tools, POLD1G10V and POLD1S746I variants have no
or only low functional impact (Table 9), which is in concordancewith our data on
these variants. In contrast, POLD1R506H and POLD1R689W are both predicted by
PON-P2 and PROVEAN to be pathogenic, while they are differently classified by
PolyPhen-2 andMutationAssessor regarding their damaging potential and func-
tional impact score, respectively, with POLD1R689W achieving a stronger functional
impairment. However, despite the predicted functional significance and pathogen-
icity of POLD1R506H, we demonstrated that in our model only POLD1R689W had a
functional impact on CHK1 phosphorylation, DNA replication, and cellular sen-
sitivity to inhibitors of the ATR pathway. Several explanations for these partly
inconsistent datamight be possible, including an inaccuracy and thus false classific-
ation by the applied prediction tools. Furthermore, the fact thatwe did not analyze
the POLD1R506H variant alone, but only in combinationwith thevariants POLD1G10V
and POLD1S746I, which could cause antagonizing or protective effects, could also be
an explanation. The existence of suchpotential “revertant”variants has alreadybeen
described for BRCA2 in a similar clinical context [6, 25]. Taken together, algorithm-
based, theoretical prediction tools to preliminarily identify pathogenic variants
might yield the most accurate estimation of pathogenicity onlywhen combined
with practical functional KOmodel systems, thus facilitating clinical-therapeutic
approaches for specific VUS.
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Table 9 | Pathogenicity for POLD1 variants according to different prediction tools
with investigated variants being highlighted
Prediction tool
Variant Citation PON-P2 PolyPhen-2 PROVEAN Mutation
Assessor
p.G10V
c.29G>T
[28] unknown
(0.398)
benign
(0.041)
neutral
(-1.407)
neutral
(0.55)
p.V295M
c.883G>A
[7] unknown
(0.703)
benign
(0.410)
neutral
(0.412)
neutral
(0.09)
p.D316H
c.946G>C
[7]
pathogenic
(0.941)
probably
damaging
(1.000)
deleterious
(-6.857)
high
(3.69)
p.D316G
c.947A>G
[7]
pathogenic
(0.919)
probably
damaging
(1.000)
deleterious
(-6.857)
high
(3.69)
p.P327L
c.981C>G
[74]
pathogenic
(0.947)
probably
damaging
(0.999)
deleterious
(-9.824)
high
(3.74)
p.S370R
c.1110C>G
[74] unknown
(0.560)
benign
(0.407)
deleterious
(-4.259)
medium
(3.115)
p.R409W
c.1225C>T
[7]
pathogenic
(0.963)
probably
damaging
(1.000)
deleterious
(-7.859)
high
(3.74)
p.G426S
c.1276G>A
[74] unknown
(0.237)
benign
(0.042)
neutral
(-0.579)
neutral
(-0.485)
p.L474P
c.1421T>C
[7, 94]
pathogenic
(0.937)
probably
damaging
(1.000)
deleterious
(-6.735)
high
(3.74)
p.S478N
c.1433G>A
[7, 74, 94]
pathogenic
(0.759)
probably
damaging
(0.998)
deleterious
(-2.820)
high
(4.215)
p.R506H
c.1517G>A
[28]
pathogenic
(0.955)
possibly
damaging
(0.755)
deleterious
(-4.922)
medium
(2.86)
p.R521Q
c.1562G>A
[7]
pathogenic
(0.957)
possibly
damaging
(0.816)
deleterious
(-3.464)
medium
(3.255)
p.R689W
c.2065C>T
[28]
pathogenic
(0.973)
probably
damaging
(0.987)
deleterious
(-7.978)
high
(4.56)
p.S746I
c.2237G>T
[28] unknown
(0.475)
benign
(0.143)
deleterious
(-3.178)
medium
(2.92)
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5.2.5 Clinical implications
Regarding a clinical-translational perspective, multiple heterozygous germline
variants in POLD1 have been identified in various cancer types, including colon,
endometrium, breast, or brain tumors [7, 74, 94]. Thus, POLD1 could represent a
tumor susceptibility gene. Most of the variants that are predicted to be functionally
significant (Table 9) are located in the proofreading exonuclease domain of POLD1,
presumably impairing the repair capacity of Polδ, and thereby conferring amutator
phenotype [60]. However, the role of variants in the polymerase active domain
of POLD1 remains unknown. In addition to POLD1R689W [60, 61] only one further
variant within the polymerase active domain, namely POLD1L604K of mice Polδ,
has been described to be potentially pathogenic [95]. Yet, there is growing evidence
that base selectivity defects, as induced by POLD1R689W, which occur in tumors,
might result in dramatic consequences for genome stability [60]. Thus, our data now
demonstrated thatvariants in the polymerase active domain of POLD1, e. g. R689W,
can be functionally significant and could confer a similar pathogenic phenotype, as
reported variantswithin the proofreading exonuclease domain.
5.2.6 Future studies
Multiple POLD1 variants in different cancers have been identified [7, 74, 94], how-
ever, their significance remains unknown. Therefore, in this dissertationwe charac-
terized several POLD1 variants, including POLD1R689W, by establishing a suitable
KOmodel and applyingmultiplemolecular read-outs. Future studies aremandatory
to further validate both the KOmodel andmolecular read-outs aswell as the clinical
significance of POLD1R689W and other known POLD1 variants. Mechanistically, we
assessed the impact of the POLD1R689W variant on the compensatory activation of
theATR pathwayand theDNA replication process. Similar to the approach byHocke
et al. [41] using siPOLD1, the effects of POLD1R689W on the cell cycle progression
and apoptosis should be investigated next. In fact, our preliminary data indicate
that S-phase arrest and an increased sub-G1 fractionwith concomitant cleavage
of PARP and caspase 3 are induced exclusively in POLD1R689W/- cells upon treat-
ment with the ATR inhibitor AZD6738. The fact that, due to the unexpected low
tumor take rate, we could only analyze fourmice in the clinically relevant group of
AZD6738-treated POLD1R689W/- tumors of the in vivo experiments, is an important
limitation of our study. Therefore, it is necessary to obtain data from additional
samples to achieve statistically unambiguous results, which is currently in progress.
The KOmodelwe established here togetherwith the appliedmolecular read-outs
represent an approach to determine the impact of certain POLD1VUS as amarker
of therapeutic response to ATR pathway inhibitors. Thus, the characterization of
more POLD1 variants in different cancer cell lines should be the aim of future stud-
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ies. For this purpose, multiple human CRC cell lineswould be available, including
SNU-C4 and its POLD1H863R variantwithin the polymerase active domain, HT115
and its POLD1R306H variant aswell as LoVo and its POLD1V312M variant, bothwithin
the proofreading exonuclease domain. Additionally, by using knock-inmodels any
other variant could be engineered and characterized. From a clinical perspective, it
would be interesting to obtain and analyze tumor samples from patients receiving
ATR inhibitors in regard to CHK1 phosphorylation, and correlate these datawith
therapeutic response. Finally, these data could provide the basis for catalogizing
POLD1 variants and their functional impact regarding the sensitization of cancer
cells to ATR pathway inhibitors.
5.3 Conclusion
This dissertationwas divided into two subprojects, characterizing on the one hand
the synthetic lethal relationship between ATR and PRIM1 by demonstrating that
PRIM1 inactivation sensitized cancer cells to ATR and CHK1 inhibitors via S-phase
stasis andWee1-mediated, caspase 8-dependent apoptosis. Variants in PRIM1 or
other componentsof thePolα-primase complex could thus represent anovel concept
for the individualized cancer therapy, as has similarly and previously been pro-
posed for POLD1 [41]. Vice versa, cancer cells naturally harboring inactivatingATR
or CHK1 variants might exhibit increased sensitivity to inhibitors targeting any
component of the Polα-primase complex. On the other hand, we demonstrated
the significant impact of the POLD1R689W variant on the cellular sensitivity to ATR
and CHK1 inhibitors in vitro and in vivo by establishing a CRISPR/Cas9-mediated
POLD1-KO model. This model along with the easily applied molecular read-out
of CHK1 phosphorylation could thus facilitate an individualized, genotype-based
concept to assess the VUS-mediated increased sensitivity of cancers to a therapy
with ATR pathway inhibitors. Taken togetherwith the in the literature identified
VUS of POLD1 and POLE [7, 74, 94] aswell as defects in other polymerases in cancer
this dissertation illustrates the emerging role of tumor-specific alterations in DNA
polymerases as novel therapeutic targets. The comprehensive identification and
functional characterization of all polymerases and their possible synthetic lethal
partners is thus essential in future studies.
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Abstract
The chemical inhibition of the kinase ATR, a central regulator of the DNA damage
response, eliminates subsets of cancer cells in different tumors. This effect is at
least partly attributable to the synthetic lethal relationship betweenATR and certain
DNA repair genes. In a previous study of our laboratory, POLD1 and PRIM1were
identified to act synthetically lethalwithATR. Thus, this dissertationwas divided
into two subprojects to characterize the synthetic lethal relationship betweenATR
and each of the two identified proteins individually.
Thefirst subproject addressed the characterizationof the synthetic lethal relation-
ship betweenATR and PRIM1, the catalytic subunit of primase of the polymerase α-
primase complex. Applying a geneticATR knock-inmodel of colorectal cancer cells,
we confirmed that siRNA-mediated PRIM1 depletion inhibits proliferation of ATR-
deficient cells, and excluded both off-target effects of the applied siRNA targeting
PRIM1, and artifacts due to clonal variation byusing anATR re-expressing cell clone.
We expanded these data by demonstrating in a panel of different cancer cell lines
that not only genetically induced ATR deficiency but also chemical inhibition of
ATR or its main effector kinase CHK1 inhibits proliferation upon PRIM1 depletion.
Mechanistically, PRIM1 depletion inATR-deficient cells caused S-phase stasiswith
no evidence for increased DNA damage followed byWee1-mediated activation of
caspase 8 and consequently of apoptosis. As PRIM1 inactivation sensitizes cancer
cells to ATR and CHK1 inhibitors, alterations in PRIM1 or other components of the
polymerase α-primase complex could represent a novel concept for the individual-
ized cancer therapy using ATR pathway inhibitors.
The second subproject addressed the further characterization of the synthetic
lethal relationship betweenATR and POLD1, the catalytic subunit of polymerase δ.
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In the previous study of our laboratory,we demonstrated that not only genetically
inducedATR deficiency but also chemical inhibition of the ATR pathway inhibits
proliferation upon POLD1 depletion. To extend these data,we now characterized
the impact of defined POLD1 variants on the sensitivity to ATR pathway inhibitors.
Therefore, we used the CRISPR/Cas9 technique in the colorectal cancer cell line
DLD-1, which harbors four heterozygous POLD1 variants, to establish heterozy-
gous POLD1-knockout cloneswith exclusive expression of distinct POLD1 variants.
These knockout clones served as amodel to determine the functional significance
of individual POLD1 variants. We demonstrated that of the four variants analyzed
onlyPOLD1R689W impairs POLD1 function, as shownbycompensatoryATRpathway
activation and impaired DNA replication. Moreover, the POLD1R689W variant in
cancer cells led to a strong decrease of cell survival in vitro and decelerated growth of
murine xenograft tumors in vivo upon treatmentwithATRpathwayinhibitors,which
further corroborates a potential clinical relevance of our data. Our here established
and characterized functional model could thus be used to complement algorithm-
basedmodels to predict the pathogenicity of tumor-specific variants of uncertain
significance, and improve their accuracy. Furthermore, our data enable a novel and
potentially clinically relevant concept for the individualized and genotype-based
therapy of POLD1-deficient cancerswith ATR pathway inhibitors.
Taken togetherwith the in the literature identified variants of uncertain signifi-
cance of POLD1 and POLE aswell as defects in other polymerases in cancer the data
of this dissertation illustrate the emerging role of tumor-specific alterations inDNA
polymerases as novel therapeutic targets. The comprehensive identification and
functional characterization of all polymerases and their possible synthetic lethal
partners is thus essential in future studies.
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Zusammenfassung
Die chemische Inhibition der Kinase ATR, einem zentralen Regulator derDNA dam-
age response, eliminiert Subpopulationenvon Krebszellen in verschiedenenTumoren.
Dieser Effekt ist zumindest teilweise der synthetisch letalen Beziehung zwischen
ATR und bestimmten DNA-Reparaturgenen zuzuschreiben. Eine frühere Studie un-
seres Labors identifizierte POLD1 und PRIM1 als synthetisch letale Partner vonATR.
Diese Dissertationwurde daher in zwei Teilprojekte untergliedert, um die synthe-
tisch letalen Beziehungen zwischen beiden PartnernmitATR zu charakterisieren.
Das erste Teilprojekt befasste sich mit der Charakterisierung der synthetisch
letalen Beziehung zwischen ATR und PRIM1, der katalytischen Untereinheit der
Primase des Polymerase α/Primase-Komplexes. Durch dieVerwendung eines gene-
tischenATR-knock-in-Modells in kolorektalen Karzinomzellen bestätigtenwir, dass
die siRNA-vermittelte PRIM1-Depletion die ProliferationATR-defizienter Zellen in-
hibiert und schlossen sowohl off-target-Effekte derverwendeten siRNAgegenPRIM1
als auch klonale Artefakte durch dieVerwendung einesATR-reexprimierenden Zell-
klons aus. Zusätzlich konntenwir zeigen, dass in einer Reihe verschiedener Krebs-
zelllinien nicht nur die genetisch induzierteATR-Defizienz, sondern auch die che-
mische InhibitionvonATR oder dessenHaupteffektorkinase CHK1 die Proliferation
nachPRIM1-Depletion inhibiert.MechanistischverursachtediePRIM1-Depletion in
ATR-defizienten Zellen eine Stagnationwährend der S-Phase ohneHinweis auf eine
erhöhteDNA-Schädigung, gefolgtvoneinerWee1-vermitteltenAktivierungvonCas-
pase 8mit anschließender Apoptose. Da also die PRIM1-Inaktivierung Krebszellen
auf ATR- und CHK1-Inhibitoren sensitiviert, könnten Defekte in PRIM1 oder ande-
ren Komponenten des Polymerase α/Primase-Komplexes ein neuartiges Konzept
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für die individualisierte Tumortherapiemittels Inhibitoren des ATR-Signalweges
darstellen.
Das zweite Teilprojekt befasste sichmit der tiefer gehenden Charakterisierung
der synthetisch letalen Beziehung zwischen ATR und POLD1, der katalytischen
Untereinheit der Polymerase δ. So konnte bereits die vorangegangene Studie aus
unserem Labor zeigen, dass sowohl die genetisch induzierte ATR-Defizienz als
auch die chemische Inhibition des ATR-Signalweges die Proliferation nach POLD1-
Depletion inhibiert. Um diese Daten zu erweitern, charakterisiertenwir nun den
Einfluss von bestimmten POLD1-Varianten auf die Sensitivität gegenüber ATR-
Signalweginhibitoren. Dazuverwendetenwir in der kolorektalen Karzinomzelllinie
DLD-1, die vier heterozygote POLD1-Varianten enthält, die CRISPR/Cas9-Methode,
um heterozygote POLD1-knockout-Klonemit ausschließlicher Expression einzel-
ner POLD1-Varianten zu etablieren. Diese knockout-Klone dienten alsModell, um
die funktionelle Bedeutung individueller POLD1-Varianten zu bestimmen. An-
hand einer kompensatorischen ATR-Signalwegaktivierung und einer beeinträch-
tigten DNA-Replikation konntenwir zeigen, dass von den vier untersuchtenVari-
anten nur POLD1R689W die POLD1-Funktion schädigte.Weiterhin verursachte die
POLD1R689W-Variante in Krebszellen eine starke Beeinträchtigung des Zellüberle-
bens in vitro und eineVerlangsamung desWachstumsmuriner Xenografttumore in
vivo nach Behandlungmit verschiedenen Inhibitoren des ATR-Signalweges. Dies
untermauert zusätzlich die potentiell klinische Relevanz unserer Daten. Unser hier
etabliertes und charakterisiertes funktionelles Modell könnte daher verwendetwer-
den, um algorithmus-basierteModelle, mit der die Pathogenität tumorspezifischer
Varianten unklarer Signifikanz vorhergesagtwird, zu komplementieren und deren
Genauigkeit zu verbessern.Weiterhin ermöglichen unsere Daten ein neues und po-
tentiell klinisch relevantes Konzept für die individualisierte und Genotyp-basierte
Therapie POLD1-defizienter Tumoremit ATR-Signalweginhibitoren.
Zusammenmit den inder Literatur identifiziertenVariantenunklarer Signifikanz
in POLD1 und POLE sowie den Defekten anderer Polymerasen in Tumoren verdeut-
lichen die Daten dieser Dissertation die zunehmende Bedeutung tumorspezifischer
Veränderungen inDNA-Polymerasen als neue therapeutische Zielstrukturen. Daher
ist eine umfassende Identifizierung und funktionelle Charakterisierung aller Poly-
merasen und ihrermöglichen synthetisch letalen Partner in zukünftigen Studien
erforderlich.
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Figure 17 | Map of the Cas9 plasmid
Schematic depiction of the Cas9 plasmid used for the KO of POLD1 in DLD-1 cells via
CRISPR/Cas9.
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Figure 18 | Map of the repair template plasmid
Schematic depiction of the repair template plasmid used for the KO of POLD1 in DLD-1
cells via CRISPR/Cas9.
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Figure 19 | PCR programs
a–e | All PCR programs used in this dissertation for the amplification of DNA fragments.
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Table 10 | PCR conditions
Primera
PCR
programb
Aim PCR product
#1–#4 (a)
genotyping of the POLD1-KO sta-
tus after CRISPR/Cas9 application
1656 bp (WTallele)
1000 bp (KO allele)
#5 +#6 (b)
genotyping of the PuroR cassette
after Cre transfection
1759 bp (Cre/loxP +)
/ (Cre/loxP -)
#7 –#12 (c)
genomic DNA amplification for se-
quencing exons 13, 17, and 18 (us-
ing primers #S2–#S4)
440 bp (exon 13)
478 bp (exon 17)
266 bp (exon 18)
#1 +#4 (a)
genomic DNA amplification for se-
quencing POLD1 exon 2a (using
primer #S1)
1656 bp
#13 +#14 (d)
mRNA amplification of POLD1 ex-
ons 2a–21, serving as template for
a nested PCRc
2581 bp
#15 +#16 (e)
amplification of the nested PCR
amplicon for sequencing POLD1
exon 13 (using primer #S5)
627 bp
#17 +#18 (e)
amplification of the nested PCR
amplicon for sequencing POLD1
exon 17 and 18 (using primer #S6)
697 bp
a according to Table 8
b according to Figure 19
c nested PCR amplicon 1:200 diluted for subsequent PCR reactions
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Figure 20 | Representative depiction of DNA fibers
Representative depiction of DNA fibers of POLD1+/+ and POLD1R689W/- cellswithout treat-
ment aswell as upon IR or HU treatment to quantify ongoing replication (red-green), stalled
forks (red), and 2nd pulse origins (green). Scale bar equals 10 µm.
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